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Genomic instability is strongly linked to the development and malignancy of cancer and by 
studying premalignant conditions we can gain a better understanding of the sources of genomic 
instability and improve cancer prevention and treatment.  The genome is very unstable in both 
premalignant and malignant conditions; however, it is unknown as to what extent different types 
of instability contribute.  Retrotransposition is an active source of genomic instability in the 
human genome and has the potential to change DNA structure and RNA expression.  
Retrotransposons are repetitive sequences that can “copy and paste” into the genome at new sites 
within an individual cell, and hundreds are known to be active in the human genome.  Despite 
the enormous influence of retrotransposons on the genome composition of many organisms, the 
degree to which they contribute to somatic genomic instability is unknown.  Because 
retrotransposition has been observed in many gastrointestinal epithelial cancer types, we focused 
on L1 mobilization as a source of instability in cancer. We hypothesized that L1 
retrotransposition is active in esophageal squamous cell carcinoma (SCC), esophageal 
adenocarcinoma (EAC), and EAC’s precursor Barrett’s esophagus (BE). To test our hypothesis, 
we evaluated 5 patients with benign BE, 5 patients with BE and concomitant esophageal 
adenocarcinoma (EAC), 10 additional patients with EAC, and 9 patients with SCC to determine 
the level of L1 activity in these diseases. Following L1-seq, we confirmed 160 somatic insertions 
by PCR in 17 of 29 individuals. We observed clonal amplification of several insertions which 
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appeared to originate in normal esophagus (NE) or BE and were later clonally expanded in BE, 
in EAC, or in SCC.  Additionally, we observed evidence of clonality within the EAC cases: 
specifically, 22 of 25 EAC-only insertions were present identically in distinct regions available 
from the same tumor, suggesting they occurred in the founding tumor cell of these lesions.  Our 
data show that somatic retrotransposition occurs early in many patients with BE and EAC, and 
indicate that early events occurring in histologically normal esophageal cells may be clonally 
expanded in esophageal adenocarcinogenesis. Additionally, we evaluated L1 ORF1 protein 
expression in 9 of the carcinoma cases for which formalin-fixed paraffin embedded tissue was 
available. Using immunohistochemistry, we detected expression of ORF1p in all tumors 
evaluated.  Interestingly, we also observed dim ORF1p expression in the normal esophagus of all 
4 patients for whom additional blocks of normal esophagus containing squamous epithelium was 
available. To determine if ORF1p expression is a hallmark of unaffected tissues, we obtained 
both skin and esophageal biopsies from two unaffected individuals.  In both biopsies, ORF1p 
expression was evident in the squamous cell epithelium.  ORF1p may be expressed in many 
normal epithelial tissues which could account for the high incidence of somatic retrotransposition 
events in epithelial cancers. Thus, our data show that L1 is weakly expressed in normal 
esophagus and retrotransposition can occur in normal tissue during the development of 
esophageal adenocarcinoma and squamous cell carcinoma.  Due to the pervasive activity of 
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Transposable elements (TE): diversity, mechanism, and contribution to human evolution 
 The human genome is a mystery which is fast being unraveled with the advent of new 
technologies and techniques for ascertaining its secrets.  One of the most surprising and 
interesting findings concerning the genome is the proportion of it which is made up of repetitive 
elements.  In 1968, Britten and Kohne were the first to observe the highly repetitive nature of the 
genome using DNA hybridization kinetics (1).  It is now known that the repeats comprising the 
genome expanded its size due to the mobility of elements first discovered in maize (2).  
McClintock observed two elements she named Activator (Ac) and Dissociator (Ds) that were 
able to transpose (i.e. transposable elements) from one chromosomal location to another and 
thereby affect the phenotype of the organism at sites termed mutable loci (2,3).  Two decades 
transpired before McClintock’s work was widely accepted; however, following its acceptance 
there have been thousands of publications throughout the scientific community concerning 
transposable elements in genomic DNA.  In fact, the seminal papers describing the sequencing of 
the human genome revealed that roughly 45 percent of its sequence was composed of 
interspersed repeats(4,5).  Transposable elements are found in all domains of life including 
Bacteria (6), Archaea (7), and Eukarya (2) and are characterized and classified based upon the 
mechanism by which they propagate.  
 DNA transposons are the first class of transposable elements and mobilize via a “cut-and-
paste” mechanism during which the element excises itself from its current location and re-inserts 
into a new one.  These elements have a propensity to insert into a new location which is proximal 
to their progenitor locus (8) and many of the elements are site specific (9).  There are many 
families of DNA transposons scattered among various species with variations in the chemical 
process of the transposition reaction; however, the critical steps are common to all elements.  
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Initially the 3’ hydroxyl groups are exposed at the transposon ends of the donor site, then a 
strand-transfer reaction occurs to integrate the element into the target site (9,10).  The strand 
transfer occurs via a nucleophilic attack on the target site by an exposed 3’ hydroxyl group.  In 
addition to this more common mechanism, there are two other mechanisms employed by 
different DNA transposons.  Helitrons (11), a DNA transposon found exclusively in eukaryotes 
that replicates via a rolling circle mechanism, and Politons/ Mavericks (12,13) encode proteins 
responsible for their self-propagation via an integrase-dependent pathway.   
 The next two classes of transposable elements are the so-called “retrotransposons” named 
for their ability to utilize a reverse transcriptase and mobilize through an RNA intermediate.  The 
retrotransposons flanked by long terminal repeats (LTR retrotransposons) are found in many 
organisms from yeast (14), to insects (15). and to mice (16).  LTR retrotransposons have an 
internal promoter in the 5’ repeat and their proteins are translated in the cytoplasm of the cell 
where their proteins and RNA form a virus-like-particle (VLP).   The VLP then enters the 
nucleus and performs reverse transcription.  The internal structure of LTRs is diverse which may 
reflect an evolutionary history of multiple time-points when the infectious retroviruses were 
unable to leave an infected cell, potentially due to their inability to form infectious particles. 
LTRs comprise approximately 8% of the human genome (4) and are thought to be largely 
transcriptionally inactive with the potential exception of  HERV-K (17).   
 The final group of retrotransposons is comprised of non-LTR retrotransposons, the only 
transposable elements known to be active in the human genome (see Figure 1.1).  These 
elements lack long terminal repeats and seem to have an evolutionary connection to group II 
introns (18,19) as they have similar mechanisms in their life cycle.  The elements also have 
shared history with telomeres because in Drosophila, telomeres are comprised of long tandem 
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arrays of two non LTR- retrotransposons (20).  These two types of retrotransposons, Het-A and 
TART, are components of a robust telomere maintenance system and were the first transposable 
elements shown to have a “bona fide role in cell structure,” (20).  In the human genome, the long 
interspersed element- 1 (LINE-1 or L1) is the only autonomous member of the family of non-
LTR retrotransposons.  Not only has L1 maintained its activity in Homo sapiens, but it also 
mobilizes many of the other examples of non-LTR retrotransposons in humans.  Active L1 
elements are approximately 6,000 nucleotides long and possess two open reading frames, ORF1 
and ORF2, which contain an RNA chaperone protein and a protein with endonuclease and 
reverse transcriptase abilities respectively (21).  L1 also has an approximately 900 nucleotide 5’ 
untranslated region and ORF2 is followed by an approximately 200 nucleotide UTR (21) and a 
poly(A) tail of varying length depending on the age of the element.  L1s are transcribed as poly-
adenylated transcripts from an internal promoter (22,23).  The ORF1 protein (ORF1p) seems to 
bind the L1 RNA as a trimer, and acts as a nucleic acid chaperone (24), and appears to be 
necessary for robust retrotransposition to occur (25–28).  The ORF1 protein is 40 kD, has an N-
terminal domain, coiled coil domain (CCD), an RNA recognition motif (RRM), and a C terminal 
domain (CTD) (29).  Additionally, ORF1p demonstrates bias toward binding its own RNA 
(26,30,31).  In recent years the structure of the ORF1p trimer has been further explored through 
crystallization (32); however, ORF2p has yet to be crystallized and therefore less is known about 
its functional mechanisms.  It is known that ORF2p is 150 kD and 1278 amino acids (as coded 
by the L1.2A allele) and has two key functions with respect to retrotransposition (25,33–36).  
ORF2p is responsible for nicking  a single strand of the double stranded DNA and reverse 
transcribing the RNA into the genome (34,36).  The ORF2 protein is thought to have four main 
components: the endonuclease domain in the N terminal region (36), a set of seven subdomains 
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of typical reverse transcriptases (37), and the third and fourth domains are of unknown function 
including the ‘Z’ segment and a 3’ cysteine-rich motif (25,38).  Clements and Singer deleted 
various regions of ORF2p in an attempt to identify domains essential to protein function outside 
of the reverse transcriptase domain (39).  The authors concluded that the octapeptide sequence 
and its adjacent amino acids in the Z region are essential for reverse transcriptase activity; 
however, the endonuclease and the cysteine rich domains are not necessary.  Furthermore, 
translation of ORF2p is unusual because of the bicistronic nature of the L1 transcript.  
Translation of ORF2p appears to predicate on the presence of an upstream ORF, an inter-ORF 
region, and may involve an IRES in mouse (40–42).  
  
 
Figure 1.1: Structural characteristics of non-LTR retrotransposons. (a) intact LINE-1 elements 
are approximately 6 kb in length, and have two open reading frames (ORF1 and ORF2) which 
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are discussed in the text.  LINE-1 elements have poly(a)-tails and are flanked by target site 
duplications (TSDs).  The 5’ UTR of the element has two promotors (indicated by the arrows) in 
both the sense and antisense directions. (b) Alu elements are ~280 bp in length and are rarely 5’ 
truncated.  The elements are comprised of two 7SL- derived monomers (e.g. the left and right 
monomers, white boxes flanking the “U”). Transcription is pol III dependent and mediated by A 
and B boxes indicated in the figure. The region in the center of the element is A-rich, Alu 
elements have poly(A) tails, and are flanked by TSDs. (c) SVA elements are highly variable in 
length because they include a variable nucleotide tandem repeat (VNTR).  The 5’ end of the 
element contains a CCCTCT repeat and two inverted Alu sequences, and the 3’ end has 
homology to the HERV-K10 right LTR (SINE-R).  SVA elements also possess poly(A) tails and 
have target site duplications (TSDs).  
The life cycle of the L1 begins with transcription of L1 RNA in the nucleus followed by 
mRNA export to the cytoplasm.  Next, the L1 mRNA bicistronic message is translated into the 
proteins ORF1 and ORF2.  The L1 RNA is bound by a trimer of ORF1 (24) and together ORF1 
and ORF2 form a ribonucleoprotein particle which travels back into the nucleus either during 
replication while the nuclear envelope is degraded, or through another currently undetermined 
mechanism along with other proteins and RNAs..  Once the RNP is in the nucleus, the 
endonuclease of ORF2 cleaves open the DNA on a single strand and the process known as 
target-primed reverse transcription (TPRT) begins (43).  The resolution in the DNA break 
created by the endonuclease of ORF2 is purported to be amended by DNA repair mechanisms in 
the cell but this process is still largely a mystery (44).  The process of TPRT also leaves target 
site duplications (TSDs) which reflect the nucleotide sequence between the initial nick made by 
the endonuclease of ORF2 and the obligate secondary break on the opposite strand of the DNA.  
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During the process of TPRT the single strand overhangs, which formed due to the single strand 
breaks on alternating strands, function as the primers in the reverse transcription reaction.  
Normally, one of the two overhangs anneals to the poly(A) tail of the RNA, the sequence 
following it is reverse transcribed using the L1 RNA as a template, and then the second strand of 
the DNA is resolved by DNA repair machinery which copies the newly integrated insertion on 
the second strand.  These TSDs are considered a hallmark of the canonical method of 
retrotransposition (45).  Occasionally during the process of TPRT, an inversion of the 5’ end of 
the element occurs and the mechanism for this has been referred to as ‘twin-priming’ (45).  In 
twin priming, one of the single stranded overhangs anneals to the poly(A) tail and the other 
anneals at an internal region of the same L1 mRNA creating an inversion near the 5’ end of the 
element (45).  The product of this process is an insertion where the first several hundred base-
pairs of the inserted, 5’ truncated L1 element sequence are in the opposite orientation to the 
remainder of the inserted sequence; e.g. base-pairs 5,000-4,000 are in the 3’-5’ orientation while 




Figure 1.2: Life cycle of the LINE-1 (L1) element.  (1) L1 RNA is transcribed from the DNA 
and processed like mRNA for export from the nucleus.  (2) The RNA is exported from the 
nucleus into the cytoplasm where ORF1p and ORF2p are translated from the bicistronic RNA.  
(3) The proteins and the L1 RNA form a complex which is then translocated into the nucleus.  
The DNA is nicked by the endonuclease domain of ORF2p and then reverse transcription occurs 
to reintegrate the L1 into a new genomic location. (4) Finally, DNA repair occurs ensuring the 
newly inserted L1 element is present on both strands and the DNA molecule is intact.   
Due to the activity and the necessity of its proteins for mobilization, the L1 is the only 
autonomous transposable element (TE) active in the human genome.  For TEs like Alu and SVA 
or processed psuedogenes to mobilize, these RNAs must ‘hijack’ the L1 machinery and are then 
assimilated into new locations in the human genome.  Although Alu elements are non-
autonomous, they are very abundant in the human genome with as many as 1 million copies 
total.  Alus are much smaller than L1 at around 300 nucleotides and do have an internal pol III 
promoter to contribute to their transcription.  Interestingly, Alu elements are notorious for 
causing non-allelic homologous recombination (NAHR) in the genome (46).  Alu elements are 
derived from two 7SL RNAs which fused prior to the evolution of primates (47).  L1 ORF2p has 
mobilized marked Alu elements in vitro using a cell culture assay (48) and there is ample 
evidence of L1’s ability to mobilize Alu elements in vivo in the human genome.  Alu elements 
also bear the hallmarks of TPRT with TSDs and poly(A) tails at the sites of insertion (49).  L1 
also mobilizes a hominid specific (50) family of elements in the human genome known as SINE-
VNTR-Alu (SVA).  SVA elements are generally 2,000 nucleotides in length and like L1 
insertions and Alus, have TSDs and poly(A) tails (49,51).  Interestingly, SVA insertions vary 
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greatly in size because of variation in the VNTR repeat region (50) and the presence or absence 
of transductions (52–54).  The elements primarily consist of four domains, in order from the 5’ 
side: (i) a CT rich repeat, also referred to as a hexamer, with CCCTCT serving as the most 
common motif, (ii) a sequence which shares homology to antisense Alu-like fragments, (iii) a 
variable number of GC-rich tandem repeats (VNTR), and an ~490 nucleotide sequence derived 
from the envelope gene and right long terminal repeat (LTR) of an extinct HERV-K10 
containing a canonical poly(A) signal.  Using the cell culture assay, ORF2 has been shown to 
mobilize SVA in vitro as well; furthermore, evidence suggests that the CT hexamer and the Alu 
like fragment of the SVA have a synergistic effect on the rate of retrotransposition (55).  In 
addition to the aforementioned non-autonomous transposable elements Alu and SVA, L1 













Retrotransposon contribution to genomic instability and disease 
L1 sequences comprise approximately 17% of the genome; however, taking into account 
the mobilized Alu, SVA, and pseudogene insertions which occurred due to L1 protein 
expression, L1 is responsible for ~33% of the sequence of the genome (4).  Most of the 
transposable elements in the human genome are no longer identifiable as TEs due to the age of 
their sequences and their sequence divergence is so great that they cannot be assigned to a single 
TE family (4,56).  The majority of the L1 elements in the human genome are not actively 
transposing because only one subfamily of each type of elements is active at a time (56,57).  
Subfamilies are determined by differences in sequence content which occur as mutations accrue 
over evolutionary time in the respective elements.  Occasionally there is overlap between L1 
subfamilies, but the overlap is usually brief (58).  The emergence of new active subfamilies of 
elements is largely due to a situation referred to as an “arms race”, a part of the ‘Red Queen’ 
hypothesis (59).  The arms race serves the purpose of evading the host defenses and the race is 
waged between both retrotransposons and the mechanisms for controlling their activity, such as 
APOBEC3 proteins (60–63).  To limit the activity of potentially mutagenic TE insertion events, 
eukaryotic cells have acquired several defense mechanisms to derail the process of L1 
mobilization at various stages. The fossils of older inactive elements are a testament to the fact 
that continued evolution of transposable elements occurs nearly constantly although the rate of 
retrotransposition has not been constant (57).  One of the main tools utilized to limit 
retrotransposition is the methylation of retrotransposon promoters to restrict the transcription of 
the elements.  Varied epigenetic modifiers are active in retrotransposition silencing, including the 
DNA methyltransferase-like protein Dnmt3L (64,65).  Dnmt3L is essential for Dnmt3A 
mediated methylation of retrotransposons in primordial germ cells (64,65). In addition there is a 
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mechanism for controlling retrotransposon activity in the germline via a piRNA specific pathway 
which mediates genome-wide CpG methylation of TEs and restricts their activity (64,66–69).  It 
has been demonstrated that L1 expression levels are inversely correlated with the methylation of 
the canonical promoter in the 5’ UTR of the element (70–72), and numerous epigenetic 
modifiers contribute to establishing and maintaining the methylation status of L1 elements in the 
genome.  To reinforce the suppression of TE activity, eukaryotic cells have also developed a 
Piwi-interacting RNA silencing pathway (A. Aravin et al., 2008; A. Aravin et al., 2006).  Piwi-
interacting RNAs, repeat associated small interfering RNAs, and microRNAs all act to degrade 
retrotransposon transcripts via RNA interference (74–79).  RNA interference is yet another 
mechanism by which the host can control TE expression using repeat-associated small 
interfering RNAs and micro-RNAs to degrade TE transcripts (61,74–76,78–84). In addition to 
epigenetic and post-transcriptional regulation of L1, there are numerous host factor proteins 
which target the process by which L1s and other retrotransposons integrate into the genome.  
Oftentimes, these host factors are also used to control retroviral infection in the host.  MOV10, a 
host factor, is a potential RNA helicase and has the ability to restrict L1 retrotransposition in cell 
culture (85–87).  MOV10 restricts TEs by associating with the key RNA-induced silencing 
complex component AGO2 and the L1 ribonucleoprotein particle (RNP).  After association with 
AGO2 and the RNP, MOV10 is theorized to degrade or block the translation of L1 RNA (88).  
The exonuclease Trex1 metabolizes reverse transcribed retrotransposon DNA to stunt the 
process of retrotransposition (89).  In addition to Trex1 and MOV10, many studies have reported 
members of the APOBEC3 (A3) family of cytidine deaminases having a role in restricting the 
activity of L1 elements in cultured cells (60,62,63,90).   
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For TE families, especially L1, to continue to propagate in the human genome, elements 
must evolve to circumvent cellular host control mechanisms.  In addition to the competition 
between the host and the TE, the TEs themselves must compete among other elements to retain 
their activity as well.  The competition among L1 elements has been demonstrated in vivo in 
studies of rodent L1s (91,92) and further supported by evidence that L1 subfamilies seem to only 
coexist when the elements contain differing 5’ UTR sequences (57).  In the mouse genome there 
are three subfamilies of active L1 elements and all have sequence differences in their 5’ UTR 
(93).   
The currently active L1 elements, L1PA1 and L1Hs, are the products of a long succession 
of L1 element evolution.  The active elements can be sub-classified based on certain ‘diagnostic’ 
nucleotides.  Elements in the transcribed group a subfamilies are referred to as ‘Ta’ elements 
(94) appeared approximately 2-3 million years ago (95,96) and have “ACA” at positions 5924-
5926 and a “G” at 6010 relative to the active L1RP element.  Older and inactive elements instead 
have a “GAG” and an “A” at the same positions.  A family which is slightly older, yet still 
active, known as the pre-Ta elements have the sequence “ACG” in place of “ACA”.  These 
diagnostic nucleotides are key factors for the selection process during the library preparation for 
this body of work which will be discussed in a subsequent chapter.   
Only a subset of the preTa and Ta L1 elements are capable of transposing to new 
locations in the genome and there are several requirements which must be met.  Because many 
L1s are 5’ truncated upon insertion, a large number of the elements are unable to promote their 
own transcription because the 5’ promoter is absent from the insertion site (97).  The 5’ 
truncations may be due to poor processivity during the reverse transcriptase reaction or 
potentially because of degradation of the L1 RNA after translation and prior to the reverse 
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transcription.  During the insertion process, oftentimes the transcript is modified and results in 
frame shifts or other inactivating mutations in either of the ORFs which causes them to be 
potentially inactive.  It has been determined that approximately 80 - 100 L1 elements are active 
in a diploid genome and are therefore able to mobilize themselves and other TEs in trans (98).  
Both copies of the L1 present in a diploid genome can generate new insertions (98).  
Additionally, there are approximately 2000-3000 Alu elements and less than 100 SVA elements 
capable of retrotransposition in the genome (99,100).  There is allelic variability between L1 
elements (101,102).  In a mechanism not dissimilar to single nucleotide polymorphisms (SNPs) 
(103), SNPs in active L1 elements can change the activity up to 16-fold (102).  A study 
comparing 3 active L1s  across ~200 haploid genomes from six geographic regions resulted in 
0% to 390% activity when compared to a reference (101).  In this study comparing a trio of L1s, 
it was also noted that one new L1 allele (i.e. the same L1 with a different nucleotide sequence 
variant) existed for every 3-5 L1s sequenced in the study.  Because the active elements are 
mobilizing to novel insertion sites in the genome, it is logical that individuals will differ with 
respect to the presence or absence of L1 insertions at loci throughout their genomes.  These 
retrotransposons insertion polymorphisms (RIPs) segregate with populations in much the same 
way that SNPs do.  Because many insertions derived from retrotransposons which are active 
occurred recently, they are polymorphic with regard to the presence or absence of the insertion in 
different human populations (95,96,104–107).  In a study using fosmid end resequencing and 
mapping to identify 6,000 nucleotide and greater structural variants, 68 non-reference L1 RIPs 
were identified (108).  Of the 68 RIPs identified, 37 were found to be “hot” or highly active 
when assayed in cell culture using the retrotransposition assay (25).  In addition to the new RIPs 
discovered, the authors noted that each of the six individuals studied possessed 2/6 insertions 
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present in the reference genome that were classified as “hot” in previous work (98).  In addition 
to the 2 aforementioned “hot” L1 elements, each individual possessed between 3 and 9 additional 
“hot” elements which were not in the reference genome (108).  Altogether, these studies 
demonstrate L1 is active and mobilizing in the genome.   
Spontaneous and inherited occurrences of disease causing mutations have been observed 
in greater than 100 cases, including diseases such as hemophilia, cancer, and diabetes (109–175) 
(see Table 1.1).  Previously, it has been suggested that ~0.27% of human genetic disease is 
caused by TE insertions (176).  An example of a somatic insertion causing disease would be a 
processed pseudogene which inserted into the CYBB gene and caused primary 
immunodeficiency(177).  Yet another example of a somatic event causing disease occurred when 
SVA mediated deletions in the NF1 gene caused disease(178).  A somatic L1 insertion caused 
Choroideremia in a patient when it inserted into the coding region of the gene(179).  There are 
many mechanisms by which TEs could disrupt normal gene expression or affect genome 
structure.  TEs can disrupt genomic sequences when they insert; however, they can also cause 
deletions and rearrangements in the genome (via 5’and 3’ transduction) (112,180).  
Transductions can occur from both non-reference and reference L1 elements and are a result of 
the weak poly(A) signal in the L1 element (158,181–183).  Because of the weak poly (A) signal, 
RNA polymerase II reads through the L1 to the adjacent DNA following the 3’ end of the 
element.  This process is estimated to occur in 15- 23% of all L1 mobilization events (158,181–
183).  An L1 mediated 3’ transduction of a novel noncoding gene into exon 67 of the dystrophin 
gene was observed; however, due to severe 5’ truncation of the element there was no 
recognizable L1 sequence present (184,185).  When L1s carry regulatory sequences in the 
transduction, “exon shuffling” can also occur which can affect gene expression (186).  Yet 
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another mechanism by which L1 insertions can cause aberrant gene expression is “gene 
breaking” (187).  For gene breaking to occur and L1 must insert into an intron in the antisense 
orientation and then split the associated transcript into two parts through the combined effects of 
the L1 polyadenylation signal and the L1 antisense promoter (187).  TEs can also provide an 
alternative promoter for a gene following their insertion into a new location.  A TE which is 
fixed in the genome or even polymorphic in the population can acquire mutations which enable 
the sequence to create a cryptic splice site (188) or it can undergo deletions which facilitate 
branch site recognition and result in Alu exonization (189).   
In addition to insertional mutagenesis, retrotransposons can mediate ectopic 
recombination through non-allelic homologous recombination (NAHR) and non-homologous 
end joining (NHEJ) in the genome (46,190–194).  In fact, a frequently observed example of this 
process is also the most frequently observed translocation in the human genome where there is a 
recombination of two Alu sequences on chromosomes 11 and 22 respectively (195).  
Additionally, it has been demonstrated that Alu repeats are enriched in segmental duplication 
breakpoints (196) and countless examples of NAHR mediated by Alu elements have been found 
(192).  Recently a broad analysis of pathogenic variants in Fanconi anemia genes found that up 
to 75% of FANCA deletions are Alu-Alu mediated, predominantly mediated by NAHR due to 
Alu Y elements (197).  Occasionally the homologous sequences of L1 elements cause mis-
alignment during meiosis and result in NAHR especially when elements are proximal to each 
other and in the same orientation (190–193).  A 520 kb deletion containing four genes occurred 
due to an L1 associated non allelic recombination and caused Ellis von Creveld syndrome in a 
family (198).  Other previous reports also noted a recombination between L1 elements flanking 
the PHKB gene (199) and a similar event occurred due to the same mechanism causing Alport 
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syndrome diffuse leiomyomatosis (173).  More recently, a deletion in the factor IX gene between 
two highly homologous L1 sequences seems to have occurred due to non-allelic-homologous 
recombination between the two tandem L1s (200).  SVA elements, through NAHR, are also 
responsible for disease-causing mutations occurring due to copy number changes with non-
recurrent breakpoints (178).  In a recent study by Vogt and colleagues, large NF1 deletions were 
studied and two of 17 deletions with non-recurrent breakpoints occurred with the concomitant 
insertion of SVA elements at the deletion breakpoints (178).   
Many of the previously described disease causing events associated with the presence of 
retrotransposons in the human genome occur during a post-zygotic stage (178) or occur in the 
germline.   Although diseases caused by insertion or aberrant recombination events have mostly 
been due to insertions prior to or during development, insertions occurring in somatic cells of 
diseased organisms have also been clearly exhibited.   Although the somatic insertions appear to 
be occurring in various regions of the brain, a subset of normal tissues, and most epithelial 
cancers, it has yet to be determined to what extent the insertions are changing gene expression 
and potentially contributing to human disease.  Somatic insertions in cancer will comprise the 
bulk of this thesis and will be further discussed in the next section (201).   
Due to the various mechanisms through which repetitive elements can cause disease, the 
host has evolved many pathways to thwart the amplification of retrotransposons and thereby the 
potential mutations which come along with them.  The defense mechanisms employed by the cell 
are diverse as they affect various aspects of the L1 life cycle.  The previously discussed L1 
control mechanisms display how the host uses multiple, if not redundant, mechanisms to control 
retrotransposon mobility and suggest when any of these mechanisms is not operating optimally 
L1 may be more active.  In other words, a cell subject to aberrant expression of its protective 
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mechanisms may be particularly susceptible to L1 somatic insertions that are inherently 





















Element Subfamily Gene Disease Chr Reference




Alu AluYb9 ABCD1 Adrenoleukodystrophy (ALD) X 113 98 20
Alu AluYa5a2 ATP7A Menkes Disease X 114 282 89
Alu AluY BTK X-linked agammaglobulinemia (XLA) X 111 N/A N/A
Alu AluY BTK X-linked agammaglobulinemia (XLA) X 115 281 74
Alu AluYb8 CD40LG Hyper-immunoglobulin M syndrome (HIGM) X 116 292 8
Alu AluYa5 CLCN5 Dent's Disease X 111,117 281 50
Alu Alu CTRC Chronic pancreatitis 1 118 31 11
Alu AluYb8 FVIII Hemophilia A X 119 290 47
Alu AluYb9 FVIII Hemophilia A X 120 288 37
Alu AluYb8 FVIII Hemophilia A X 121 FL N/A
Alu AluYa5a2 FIX Hemophilia B X 122 244 78
Alu AluYa5a2 FIX Hemophilia B X 123 237 39
Alu AluY FIX Hemophilia B X 124 279 40
Alu AluYc1 GK Glycerol kinase deficiency (GKD) X 125 241 74
Alu AluYa5 IL2RG X-linked (XSCID) X 111 N/A N/A
Alu AluY CRB1 Retinitis pigmentosa (RP) 1 126 244 70
Alu Alu SERPINC1 Type 1 autoimmune thyroid disease (ATD) 1 127 6 40
Alu AluYa5 ALMS1 Alström syndrome 2 111 257 76
Alu AluJ MSH2
Lynch syndrome or hereditary nonpolyposis colorectal 
cancer (HNPCC)
2 128 85 40
Alu N/A MSH2 Hereditary Cancer 2 175 N/A N/A
Alu AluYa5 ZFHX1B Mowat-Wilson syndrome 2 111 281 93
Alu AluYb9 BCHE Cholinesterase deficiency 3 129 289 38
Alu AluYa5 CASR
Familial hypocalciuric hypercalcemia and neonatal severe 
hyperparathyroidism (FHH and NSHPT)
3 130 280 93
Alu AluYb8 HESX1 Anterior Pituitary Aplasia 3 131 288 30
Alu AluYb8 OPA1 Autosomal dominant optic atrophy (ADOA) 3 132 289 25
Alu AluYa5 MLVI2 Associated with leukemia* 5 133 280 26
Alu AluYb8 APC Hereditary desmoid disease (HDD)* 5 134 278 40
Alu N/A APC Hereditary cancer 5 175 N/A N/A
Alu AluYb9 APC Familial adenomatous polyposis (FAP) 5 135 93 60
Alu AluY MCC hepatocellular carcinoma 5 144 N/A N/A
Alu AluYb8 MAK Retinitis pigmentosa (RP) 6 136 281 57
Alu AluYa5 NT5C3 Chronic hemolytic leukemia (CHL) 7 137 281 36
Alu AluY CFTR Cystic Fibrosis 7 138 46 57
Alu AluYa5 CFTR Cystic Fibrosis 7 138 281 56
Alu AluYa5 EYA1 Brancio-oto-renal (BOR) syndrome 8 139 N/A 97
Alu AluYb9 LPL Lipoprotein disease (LPL) deficiency 8 111 150 60
Alu AluYb5/8 CHD7 CHARGE syndrome 8 140 75 100
Alu AluYa5 POMT1 Walker Walburg syndrome 9 141 290 53
Alu AluYa5 FGFR2 Apert syndrome 10 142 283 69
Alu AluYb8 FGFR2 Apert syndrome 10 142 288 47
Alu AluYk13 FGFR2 Apert syndrome 10 143 214 12
Alu AluYa5 FAS Autoimmune lymphoproliferative syndrome (ALPS) 10 144 281 33
Alu AluYc1 SERPING1 Hereditary form of angioedma (HAE) 11 145 285 42
Alu AluYa5 HMBS Acute intermittant prophyria (AIP) 11 146 279 39
Alu N/A ATM Hereditay cancer 11 175 N/A N/A
Alu AluYa5 GNPTAB Mucopolydosis Type II (ML II) 12 147 279 17
Alu AluYc1 BRCA2 Breast Cancer 13 148 281 62
Alu N/A BRCA2 Breast Cancer 13 175 N/A N/A
Alu N/A BRCA2 Breast Cancer 13 175 N/A N/A
Alu N/A BRCA2 Breast Cancer 13 175 N/A N/A
Alu N/A BRCA2 Breast Cancer 13 175 N/A N/A
Alu N/A BRCA2 Breast Cancer 13 175 N/A N/A
Alu N/A BRCA2 Breast Cancer 13 175 N/A N/A
Alu N/A BRCA2 Breast Cancer 13 175 N/A N/A
Alu N/A BRCA2 Breast Cancer 13 175 N/A N/A
Alu AluYa5 BRCA2 Breast Cancer 13 149 285 N/A
Alu N/A PALB2 Hereditary cancer 16 175 N/A N/A
Alu AluYb8 PMM2 Congenital disorders of glycosylation type Ia (CDG-Ia) 16 150 263 10
Alu AluYc1 BRCA1 Breast and Ovarian Cancer, Familial 17 151 191 60
Alu N/A BRCA1 Hereditary Cancer 17 175 N/A N/A
Alu AluS BRCA1 Breast Cancer 17 149 286 N/A
Alu AluYa5 NF1 Neurofibromatosis type 1 (NF1, cancer)* 17 152 282 40
Alu AluY NF1 Neurofibromatosis type 1 (NF1, cancer) 17 153 280 N/A
Alu AluY NF1 Neurofibromatosis type 1 (NF1, cancer) 17 153 281 N/A
Alu AluYa5 NF1 Neurofibromatosis type 1 (NF1, cancer) 17 153 282 60
Alu AluYa5 NF1 Neurofibromatosis type 1 (NF1, cancer) 17 153 284 120
Alu AluYa5 NF1 Neurofibromatosis type 1 (NF1, cancer) 17 153 281 N/A
Alu AluYa5 NF1 Neurofibromatosis type 1 (NF1, cancer) 17 153 284 110
Alu AluYa5 NF1 Neurofibromatosis type 1 (NF1, cancer) 17 153 279 N/A
Alu AluYa5 NF1 Neurofibromatosis type 1 (NF1, cancer) 17 153 264 60-85
Alu AluYb8 NF1 Neurofibromatosis type 1 (NF1, cancer) 17 153 249 121
Alu AluYb8 NF1 Neurofibromatosis type 1 (NF1, cancer) 17 153 288 N/A
Alu AluYb8 NF1 Neurofibromatosis type 1 (NF1, cancer) 17 153 289 120
Alu AluYb8 NF1 Neurofibromatosis type 1 (NF1, cancer) 17 153 288 78-178
Alu AluYb8 NF1 Neurofibromatosis type 1 (NF1, cancer) 17 153 288 118
Alu AluYb8 NF1 Neurofibromatosis type 1 (NF1, cancer) 17 153 268 121
LINE-1 L1 Ta CYBB Chronic granulomatous disease (CGD) X 154, 155 1722 101
LINE-1 L1 Ta CYBB Chronic granulomatous disease (CGD) X 155 836 69
LINE-1 L1 Ta CHM Choroideremia X 116 6,017 71
LINE-1 L1 Ta DMD Duchenne muscular dystrophy (DMD) X 156 452 41
LINE-1 L1 Ta DMD Duchenne muscular dystrophy (DMD) X 157 608 16
LINE-1 L1 Ta DMD Duchenne muscular dystrophy (DMD) X 111 1400 38
LINE-1 L1 Ta DMD Duchenne muscular dystrophy (DMD) X 158 530 73
LINE-1 N/A DMD Duchenne muscular dystrophy (DMD) X E Bakker & G van Omenn, pers.comm. 878 N/A
LINE-1 L1 Ta DMD Duchenne muscular dystrophy (DMD) X 122, 123 212 118
LINE-1 L1 Ta FVIII Hemophilia A X 109 3800 54
LINE-1 L1 preTa FVIII Hemophilia A X 109 2300 77
LINE-1 L1 Ta FIX Hemophilia B X 124 463 68
LINE-1 L1 Ta FIX Hemophilia B X 159 163 125
LINE-1 L1 Ta RP2 X linked retinitis pigmentosa(XLRP) X 111 6000 64
LINE-1 L1 HS RPS6KA3 Coffin-Lowry Syndrome X 111 2800 N/A
LINE-1 N/A ABDH5 Chanaric-Dorfman syndrome (CDS) 3 Sprecher pers. comm. FL N/A
LINE-1 N/A MLH1 Hereditary Cancer 3 175 N/A N/A
LINE-1 N/A MLH1 Hereditary Cancer 3 175 N/A N/A
LINE-1 L1 Ta APC Colon cancer 5 176 520 222
LINE-1 L1 Hs EYA1 Branchio-oto-renal syndrome (BOR) 8 160 3756 None
LINE-1 L1 Ta ST18 Hepatocellular carcinoma* 8 144 410 N/A
LINE-1 L1 Ta FKTN Fukuyama muscular dystrophy (FCMD) 9 161 1200 59
LINE-1 L1 Ta FKTN Fukuyama muscular dystrophy (FCMD) 9 161 3000 N/A
LINE-1 L1 Hs SETX Ataxia with oculomotor apraxia type 2 (AOA2) 9 162 1300 42
LINE-1 L1 Ta HBB β thalassemia 11 163 6000 107
LINE-1 L1 Hs PDHX PHHc deficiency 11 164 6086 67
LINE-1 L1 Ta SLCO1B3 Rotor syndrome 12 165 6,100 N/A
LINE-1 L1 preTa NF1 Neurofibromatosis type 1 (NF1, cancer) 17 153 1800 N/A
LINE-1 L1 Ta NF1 Neurofibromatosis type 1 (NF1, cancer) 17 153 6,000 N/A
LINE-1 N/A NF1 Neurofibromatosis type 1 (NF1, cancer) 17 153 2200 N/A
LINE-1 L1 Ta PTEN Endometrial carcioma 149 112 N/A
SVA F FVIX Hemophilia B X 166 2524 28
SVA F1 SUZ1P Neurofibromatosis type 1 (NF1, cancer)* 115 1700 23
SVA F SUZ1P Neurofibromatosis type 1 (NF1, cancer)* 115 1300 40
SVA F BTK X linked agammaglobulinemia (XLA) X 115 251 92
SVA F TAF1 X linked dystonia-parkinonism syndrome (XDP) X 167 2627 62
SVA E LDRAP1 Autosomal recessive hypercholesterolaemia (ARH) 1 168 2600 57
SVA E SPTA1
Hereditary Elliptoytosis and Hereditary Pyropoikilocytosis 
(HE and HPP)
1 111 632 50
SVA F HLA-A Leukemia 6 169 2000 45
SVA F PMS2 Lynch syndrome 7 202 2200 N/A
SVA E FKTN Fukuyama muscular dystrophy (FCMD) 9 170,171 3023 32
SVA E PNPLA2 Neuroal lipid storage disease with myopathy (NLSDM) 11 172 1800 44
pA N/A COL4A6 Alport syndrome X 173 N/A 70
pA N/A AGA Aspartylglucosaminuria (AGU) 4 111 N/A 37
pA N/A BRCA2 breast cancer 13 174 N/A 35
pA N/A NF1 Neurofibromatosis type 1 (NF1, cancer) 17 153 N/A 120
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Alu AluYb9 ABCD1 Adrenoleukodystrophy (ALD) X 113 98 20
Alu AluYa5a2 ATP7A Menkes Disease X 114 282 89
Alu AluY BTK X-linked agammaglobulinemia (XLA) X 111 N/A N/A
Alu AluY BTK X-linked agammaglobulinemia (XLA) X 115 281 74
Alu AluYb8 CD40LG Hyper-immunoglobulin M syndrome (HIGM) X 116 292 8
Alu AluYa5 CLCN5 Dent's Disease X 111,117 281 50
Alu Alu CTRC Chronic pancreatitis 1 118 31 11
Alu AluYb8 FVIII Hemophilia A X 119 290 47
Alu AluYb9 FVIII Hemophilia A X 120 288 37
Alu AluYb8 FVIII Hemophilia A X 121 FL N/A
Alu AluYa5a2 FIX Hemophilia B X 122 244 78
Alu AluYa5a2 FIX Hemophilia B X 123 237 39
Alu AluY FIX Hemophilia B X 124 279 40
Alu AluYc1 GK Glycerol kinase deficiency (GKD) X 125 241 74
Alu AluYa5 IL2RG X-linked (XSCID) X 111 N/A N/A
Alu AluY CRB1 Retinitis pigmentosa (RP) 1 126 244 70
Alu Alu SERPINC1 Type 1 autoimmune thyroid disease (ATD) 1 127 6 40
Alu AluYa5 ALMS1 Alström syndrome 2 111 257 76
Alu AluJ MSH2
Lynch syndrome or hereditary nonpolyposis colorectal 
cancer (HNPCC)
2 128 85 40
Alu N/A MSH2 Hereditary Cancer 2 175 N/A N/A
Alu AluYa5 ZFHX1B Mowat-Wilson syndrome 2 111 281 93
Alu AluYb9 BCHE Cholinesterase deficiency 3 129 289 38
Alu AluYa5 CASR
Familial hypocalciuric hypercalcemia and neonatal severe 
hyperparathyroidism (FHH and NSHPT)
3 130 280 93
Alu AluYb8 HESX1 Anterior Pituitary Aplasia 3 131 288 30
Alu AluYb8 OPA1 Autosomal dominant optic atrophy (ADOA) 3 132 289 25
Alu AluYa5 MLVI2 Associated with leukemia* 5 133 280 26
Alu AluYb8 APC Hereditary desmoid disease (HDD)* 5 134 278 40
Alu N/A APC Hereditary cancer 5 175 N/A N/A
Alu AluYb9 APC Familial adenomatous polyposis (FAP) 5 135 93 60
Alu AluY MCC hepatocellular carcinoma 5 144 N/A N/A
Alu AluYb8 MAK Retinitis pigmentosa (RP) 6 136 281 57
Alu AluYa5 NT5C3 Chronic hemolytic leukemia (CHL) 7 137 281 36
Alu AluY CFTR Cystic Fibrosis 7 138 46 57
Alu AluYa5 CFTR Cystic Fibrosis 7 138 281 56
Alu AluYa5 EYA1 Brancio-oto-renal (BOR) syndrome 8 139 N/A 97
Alu AluYb9 LPL Lipoprotein disease (LPL) deficiency 8 111 150 60
Alu AluYb5/8 CHD7 CHARGE syndrome 8 140 75 100
Alu AluYa5 POMT1 Walker Walburg syndrome 9 141 290 53
Alu AluYa5 FGFR2 Apert syndrome 10 142 283 69
Alu AluYb8 FGFR2 Apert syndrome 10 142 288 47
Alu AluYk13 FGFR2 Apert syndrome 10 143 214 12
Alu AluYa5 FAS Autoimmune lymphoproliferative syndrome (ALPS) 10 144 281 33
Alu AluYc1 SERPING1 Hereditary form of angioedma (HAE) 11 145 285 42
Alu AluYa5 HMBS Acute intermittant prophyria (AIP) 11 146 279 39
Alu N/A ATM Hereditay cancer 11 175 N/A N/A
Alu AluYa5 GNPTAB Mucopolydosis Type II (ML II) 12 147 279 17
Alu AluYc1 BRCA2 Breast Cancer 13 148 281 62
Alu N/A BRCA2 Breast Cancer 13 175 N/A N/A
Alu N/A BRCA2 Breast Cancer 13 175 N/A N/A
Alu N/A BRCA2 Breast Cancer 13 175 N/A N/A
Alu N/A BRCA2 Breast Cancer 13 175 N/A N/A
Alu N/A BRCA2 Breast Cancer 13 175 N/A N/A
Alu N/A BRCA2 Breast Cancer 13 175 N/A N/A
Alu N/A BRCA2 Breast Cancer 13 175 N/A N/A
Alu N/A BRCA2 Breast Cancer 13 175 N/A N/A
Alu AluYa5 BRCA2 Breast Cancer 13 149 285 N/A
Alu N/A PALB2 Hereditary cancer 16 175 N/A N/A
Alu AluYb8 PMM2 Congenital disorders of glycosylation type Ia (CDG-Ia) 16 150 263 10
Alu AluYc1 BRCA1 Breast and Ovarian Cancer, Familial 17 151 191 60
Alu N/A BRCA1 Hereditary Cancer 17 175 N/A N/A
Alu AluS BRCA1 Breast Cancer 17 149 286 N/A
Alu AluYa5 NF1 Neurofibromatosis type 1 (NF1, cancer)* 17 152 282 40
Alu AluY NF1 Neurofibromatosis type 1 (NF1, cancer) 17 153 280 N/A
Alu AluY NF1 Neurofibromatosis type 1 (NF1, cancer) 17 153 281 N/A
Alu AluYa5 NF1 Neurofibromatosis type 1 (NF1, cancer) 17 153 282 60
Alu AluYa5 NF1 Neurofibromatosis type 1 (NF1, cancer) 17 153 284 120
Alu AluYa5 NF1 Neurofibromatosis type 1 (NF1, cancer) 17 153 281 N/A
Alu AluYa5 NF1 Neurofibromatosis type 1 (NF1, cancer) 17 153 284 110
Alu AluYa5 NF1 Neurofibromatosis type 1 (NF1, cancer) 17 153 279 N/A
Alu AluYa5 NF1 Neurofibromatosis type 1 (NF1, cancer) 17 153 264 60-85
Alu AluYb8 NF1 Neurofibromatosis type 1 (NF1, cancer) 17 153 249 121
Alu AluYb8 NF1 Neurofibromatosis type 1 (NF1, cancer) 17 153 288 N/A
Alu AluYb8 NF1 Neurofibromatosis type 1 (NF1, cancer) 17 153 289 120
Alu AluYb8 NF1 Neurofibromatosis type 1 (NF1, cancer) 17 153 288 78-178
Alu AluYb8 NF1 Neurofibromatosis type 1 (NF1, cancer) 17 153 288 118
Alu AluYb8 NF1 Neurofibromatosis type 1 (NF1, cancer) 17 153 268 121
LINE-1 L1 Ta CYBB Chronic granulomatous disease (CGD) X 154, 155 1722 101
LINE-1 L1 Ta CYBB Chronic granulomatous disease (CGD) X 155 836 69
LINE-1 L1 Ta CHM Choroideremia X 116 6,017 71
LINE-1 L1 Ta DMD Duchenne muscular dystrophy (DMD) X 156 452 41
LINE-1 L1 Ta DMD Duchenne muscular dystrophy (DMD) X 157 608 16
LINE-1 L1 Ta DMD Duchenne muscular dystrophy (DMD) X 111 1400 38
LINE-1 L1 Ta DMD Duchenne muscular dystrophy (DMD) X 158 530 73
LINE-1 N/A DMD Duchenne muscular dystrophy (DMD) X E Bakker & G van Omenn, pers.comm. 878 N/A
LINE-1 L1 Ta DMD Duchenne muscular dystrophy (DMD) X 122, 123 212 118
LINE-1 L1 Ta FVIII Hemophilia A X 109 3800 54
LINE-1 L1 preTa FVIII Hemophilia A X 109 2300 77
LINE-1 L1 Ta FIX Hemophilia B X 124 463 68
LINE-1 L1 Ta FIX Hemophilia B X 159 163 125
LINE-1 L1 Ta RP2 X linked retinitis pigmentosa(XLRP) X 111 6000 64
LINE-1 L1 HS RPS6KA3 Coffin-Lowry Syndrome X 111 2800 N/A
LINE-1 N/A ABDH5 Chanaric-Dorfman syndrome (CDS) 3 Sprecher pers. comm. FL N/A
LINE-1 N/A MLH1 Hereditary Cancer 3 175 N/A N/A
LINE-1 N/A MLH1 Hereditary Cancer 3 175 N/A N/A
LINE-1 L1 Ta APC Colon cancer 5 176 520 222
LINE-1 L1 Hs EYA1 Branchio-oto-renal syndrome (BOR) 8 160 3756 None
LINE-1 L1 Ta ST18 Hepatocellular carcinoma* 8 144 410 N/A
LINE-1 L1 Ta FKTN Fukuyama muscular dystrophy (FCMD) 9 161 1200 59
LINE-1 L1 Ta FKTN Fukuyama muscular dystrophy (FCMD) 9 161 3000 N/A
LINE-1 L1 Hs SETX Ataxia with oculomotor apraxia type 2 (AOA2) 9 162 1300 42
LINE-1 L1 Ta HBB β thalassemia 11 163 6000 107
LINE-1 L1 Hs PDHX PHHc deficiency 11 164 6086 67
LINE-1 L1 Ta SLCO1B3 Rotor syndrome 12 165 6,100 N/A
LINE-1 L1 preTa NF1 Neurofibromatosis type 1 (NF1, cancer) 17 153 1800 N/A
LINE-1 L1 Ta NF1 Neurofibromatosis type 1 (NF1, cancer) 17 153 6,000 N/A
LINE-1 N/A NF1 Neurofibromatosis type 1 (NF1, cancer) 17 153 2200 N/A
LINE-1 L1 Ta PTEN Endometrial carcioma 149 112 N/A
SVA F FVIX Hemophilia B X 166 2524 28
SVA F1 SUZ1P Neurofibromatosis type 1 (NF1, cancer)* 115 1700 23
SVA F SUZ1P Neurofibromatosis type 1 (NF1, cancer)* 115 1300 40
SVA F BTK X linked agammaglobulinemia (XLA) X 115 251 92
SVA F TAF1 X linked dystonia-parkinonism syndrome (XDP) X 167 2627 62
SVA E LDRAP1 Autosomal recessive hypercholesterolaemia (ARH) 1 168 2600 57
SVA E SPTA1
Hereditary Elliptoytosis and Hereditary Pyropoikilocytosis 
(HE and HPP)
1 111 632 50
SVA F HLA-A Leukemia 6 169 2000 45
SVA F PMS2 Lynch syndrome 7 202 2200 N/A
SVA E FKTN Fukuyama muscular dystrophy (FCMD) 9 170,171 3023 32
SVA E PNPLA2 Neuroal lipid storage disease with myopathy (NLSDM) 11 172 1800 44
pA N/A COL4A6 Alport syndrome X 173 N/A 70
pA N/A AGA Aspartylglucosaminuria (AGU) 4 111 N/A 37
pA N/A BRCA2 breast cancer 13 174 N/A 35
pA N/A NF1 Neurofibromatosis type 1 (NF1, cancer) 17 153 N/A 120
PP** TMF1 CYBB Chronic granulomatous disease (CGD) X 114 5800 100
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Alu AluYb9 ABCD1 Adrenoleukodystrophy (ALD) X 113 98 20
Alu AluYa5a2 ATP7A Menkes Disease X 114 282 89
Alu AluY BTK X-linked agammaglobulinemia (XLA) X 111 N/A N/A
Alu AluY BTK X-linked agammaglobulinemia (XLA) X 115 281 74
Alu AluYb8 CD40LG Hyper-immunoglobulin M syndrome (HIGM) X 116 292 8
Alu AluYa5 CLCN5 Dent's Disease X 111,117 281 50
Alu Alu CTRC Chronic pancreatitis 1 118 31 11
l l b8 FVIII Hemophilia A X 19 90 47
l l b9 FVIII Hemophilia A X 20 88 37
l l b8 FVIII Hemophilia A X 21 FL N/A
lu luYa5a2 FIX Hemophilia B X 122 244 78
Alu AluYa5a2 FIX Hemophilia B X 123 237 39
Alu AluY FIX Hemophilia B X 124 279 40
Alu AluYc1 GK Glycerol kinase deficiency (GKD) X 125 241 74
Alu AluYa5 IL2RG X-linked (XSCID) X 111 N/A N/A
Alu AluY CRB1 Retinitis pigmentosa (RP) 1 126 244 70
Alu Alu SERPINC1 Type 1 autoimmune thyroid disease (ATD) 1 127 6 40
Alu AluYa5 ALMS1 Alström syndrome 2 111 257 76
Alu AluJ MSH2
Lynch syndrome or hereditary nonpolyposis colorectal 
cancer (HNPCC)
2 128 85 40
Alu N/A MSH2 Hereditary Cancer 2 75 N/A N/A
Alu AluY 5 ZFHX1B Mowat-Wilson syndrome 2 11 281 93
Alu AluYb9 BCHE Cholinesterase deficiency 3 29 289
Alu AluYa5 CASR
Familial hypocalciuric hypercalcemia and neonatal severe 
hyperparathyroidism (FHH and NSHPT)
3 130 280 93
Alu AluYb8 HESX1 Anterior Pituitary Aplasia 3 131 288 30
Alu AluYb8 OPA1 Autosomal dominant optic atrophy (ADOA) 3 132 289 25
Alu AluYa5 MLVI2 Associated with leukemia* 5 133 280 26
Alu AluYb8 APC Hereditary desmoid disease (HDD)* 5 134 278 40
Alu N/A APC Hereditary cancer 5 175 N/A N/A
Alu AluYb9 APC Familial adenomatous polyposis (FAP) 5 135 93 60
Alu AluY MCC hepatocellular carcinoma 5 144 N/A N/A
Alu AluYb8 MAK Retinitis pigmentosa (RP) 6 136 281 57
Alu AluYa5 NT5C3 Chronic hemolytic leukemia (CHL) 7 137 281 36
Alu AluY CFTR Cystic Fibrosis 7 38 46 57
Alu AluYa5 CFTR Cystic Fibrosis 7 38 281 56
Alu AluY 5 EYA1 Brancio-oto-renal (BOR) syndrome 8 39 N/A 97
Alu AluYb9 LPL Lipoprotein dis ase (LPL) deficiency 11 150 60
Alu AluYb5/8 CHD7 CHARGE syndrome 8 140 75 100
Alu AluYa5 POMT1 Walker Walburg syndrome 9 141 290 53
Alu AluYa5 FGFR2 Apert syndrome 10 142 283 69
Alu AluYb8 FGFR2 Apert syndrome 10 142 288 47
Alu AluYk13 FGFR2 Apert syndrome 10 143 214 12
Alu AluYa5 FAS Autoimmune lymphoproliferative syndrome (ALPS) 10 144 281 33
Alu AluYc1 SERPING1 Hereditary form of angioedma (HAE) 11 145 285 42
Alu AluYa5 HMBS Acute intermittant prophyria (AIP) 11 146 279 39
Alu N/A ATM Hereditay cancer 11 175 N/A N/A
Alu AluYa5 GNPTAB Mucopolydosis Type II (ML II) 12 147 279 17
Alu AluYc1 BRCA2 Breast Cancer 13 148 281 62
Alu N/A BRCA2 Breast Cancer 3 75 N/A /
Alu N/A BRCA2 Br ast Cancer 13 75 N/A N/A
Alu N/A BRCA2 Breast Cancer 13 175 N/A N/A
Alu N/A BRCA2 Breast Cancer 13 175 N/A N/A
Alu N/A BRCA2 Breast Cancer 13 175 N/A N/A
Alu N/A BRCA2 Breast Cancer 13 175 N/A N/A
Alu N/A BRCA2 Breast Cancer 13 175 N/A N/A
Alu N/A BRCA2 Breast Cancer 13 175 N/A N/A
Alu AluYa5 BRCA2 Breast Cancer 13 149 285 N/A
Alu N/A PALB2 Hereditary cancer 16 175 N/A N/A
Alu AluYb8 PMM2 Congenital disorders of glycosylation type Ia (CDG-Ia) 16 150 263 10
Alu AluYc1 BRCA1 Breast and Ovaria  Cancer, Familial 1 151 191 60
Alu N/A BRCA1 Hereditary Cancer 17 175 N/A N/A
Alu AluS BRCA1 Breast Cancer 7 49 2 6 N/A
Alu AluYa5 NF1 Neurofibromatosis type 1 (NF1, cancer)* 17 152 282 40
Alu AluY NF1 Neurofibromatosis type 1 (NF1, cancer) 17 153 280 N/A
Alu AluY NF1 Neurofibromatosis type 1 (NF1, cancer) 17 153 281 N/A
Alu AluYa5 NF1 Neurofibromatosis type 1 (NF1, cancer) 17 153 282 60
Alu AluYa5 NF1 Neurofibromatosis type 1 (NF1, cancer) 17 153 284 120
Alu AluYa5 NF1 Neurofibromatosis type 1 (NF1, cancer) 17 153 281 N/A
Alu AluYa5 NF1 Neurofibromatosis type 1 (NF1, cancer) 17 153 284 110
Alu AluYa5 NF1 Neurofibromatosis type 1 (NF1, cancer) 17 153 279 N/A
Alu AluYa5 NF1 Neurofibromatosis type 1 (NF1, cancer) 17 153 264 60-85
Alu AluYb8 NF1 Neurofibromatosis type 1 (NF1, cancer) 17 153 249 121
Alu AluYb8 NF1 Neurofibromatosis type 1 (NF1, cancer) 17 153 288 N/A
Alu AluYb8 NF1 Neurofibromatosis type 1 (NF1, cancer) 17 153 289 120
Alu AluYb8 NF1 Neurofibromatosis type 1 (NF1, cancer) 17 153 288 78-178
Alu AluYb8 NF1 Neurofibromatosis type 1 (NF1, cancer) 17 153 288 118
Alu AluYb8 NF1 Neurofibromatosis type 1 (NF1, cancer) 17 153 268 121
LINE-1 L1 Ta CYBB Chronic granulomatous disease (CGD) X 154, 155 1722 101
LINE-1 L1 Ta CYBB Chronic granulomatous disease (CGD) X 155 836 69
LINE-1 L1 Ta CHM Choroideremia X 116 6,017 71
LINE-1 L1 Ta DMD Duchenne muscular dystrophy (DMD) X 156 452 41
LINE-1 L1 Ta DMD Duchenne muscular dystrophy (DMD) X 157 608 16
LINE-1 L1 Ta DMD Duchenne muscular dystrophy (DMD) X 111 1400 38
LINE-1 L1 Ta DMD Duchenne muscular dystrophy (DMD) X 158 530 73
LINE-1 N/A DMD Duchenne muscular dystrophy (DMD) X E Bakker & G van Omenn, pers.comm. 878 N/A
LINE-1 L1 Ta DMD Duchenne muscular dystrophy (DMD) X 122, 123 212 118
LINE-1 L1 Ta FVIII Hemophilia A X 109 3800 54
LINE-1 L1 preTa FVIII Hemophilia A X 109 2300 77
LINE-1 L1 Ta FIX Hemophilia B X 124 463 68
LINE-1 L1 Ta FIX Hemophilia B X 159 163 125
LINE-1 L1 Ta RP2 X linked retinitis pigmentosa(XLRP) X 111 6000 64
LINE-1 L1 HS RPS6KA3 Coffin-Lowry Syndrome X 111 2800 N/A
LINE-1 N/A ABDH5 Chanaric-Dorfman syndrome (CDS) 3 Sprecher pers. comm. FL N/A
LINE-1 N/A MLH1 Hereditary Cancer 3 175 N/A N/A
LINE-1 N/A MLH1 Hereditary Cancer 3 175 N/A N/A
LINE-1 L1 Ta APC Colon cancer 5 176 520 222
LINE-1 L1 Hs EYA1 Branchio-oto-renal syndrome (BOR) 8 160 3756 None
LINE-1 L1 Ta ST18 Hepatocellular carcinoma* 8 144 410 N/A
LINE-1 L1 Ta FKTN Fukuyama muscular dystrophy (FCMD) 9 161 1200 59
LINE-1 L1 Ta FKTN Fukuyama muscular dystrophy (FCMD) 9 161 3000 N/A
LINE-1 L1 Hs SETX Ataxia with oculomotor apraxia type 2 (AOA2) 9 162 1300 42
LINE-1 L1 Ta HBB β thalassemia 11 163 6000 107
LINE-1 L1 Hs PDHX PHHc deficiency 11 164 6086 67
LINE-1 L1 Ta SLCO1B3 Rotor syndrome 12 165 6,100 N/A
LINE-1 L1 preTa NF1 Neurofibromatosis type 1 (NF1, cancer) 17 153 1800 N/A
LINE-1 L1 Ta NF1 Neurofibromatosis type 1 (NF1, cancer) 17 153 6,000 N/A
LINE-1 N/A NF1 Neurofibromatosis type 1 (NF1, cancer) 17 153 2200 N/A
LINE-1 L1 Ta PTEN Endometrial carcioma 149 112 N/A
SVA F FVIX Hemophilia B X 166 2524 28
SVA F1 SUZ1P Neurofibromatosis type 1 (NF1, cancer)* 115 1700 23
SVA F SUZ1P Neurofibromatosis type 1 (NF1, cancer)* 115 1300 40
SVA F BTK X linked agammaglobulinemia (XLA) X 115 251 92
SVA F TAF1 X linked dystonia-parkinonism syndrome (XDP) X 167 2627 62
SVA E LDRAP1 Autosomal recessive hypercholesterolaemia (ARH) 1 168 2600 57
SVA E SPTA1
Hereditary Elliptoytosis and Hereditary Pyropoikilocytosis 
(HE and HPP)
1 111 632 50
SVA F HLA-A Leukemia 6 169 2000 45
SVA F PMS2 Lynch syndrome 7 202 2200 N/A
SVA E FKTN Fukuyama muscular dystrophy (FCMD) 9 170,171 3023 32
SVA E PNPLA2 Neuroal lipid storage disease with myopathy (NLSDM) 11 172 1800 44
pA N/A COL4A6 Alport syndrome X 173 N/A 70
pA N/A AGA Aspartylglucosaminuria (AGU) 4 111 N/A 37
pA N/A BRCA2 breast cancer 13 174 N/A 35
pA N/A NF1 Neurofibromatosis type 1 (NF1, cancer) 17 153 N/A 120
PP** TMF1 CYBB Chronic granulomatous disease (CGD) X 114 5800 100
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Table 1.1: Disease-causing retrotransposon insertions. This table details an up to date list of all 
known disease causing retrotransposon mediated mutations.  The diseases with a * following 
their name indicate insertions which are known to be somatic.  In this table, the type of element 
and the location into which it inserted, the disease caused by the insertion, the size of the 

















L1 and Cancer 
It follows logically that genetic instability caused by retrotransposition activity would be 
elevated in diseases where normal cellular check points during proliferation and DNA replication 
are absent, such as cancer.  Indeed, many cancers have shown high L1 expression and a high 
occurrence of somatic insertions in patients evaluated thus far (202–210).  Although L1 activity 
in cancer, especially epithelial cancers, is prevalent, it is still unclear how much somatic 
retrotransposon insertions are contributing to oncogenesis.  Furthermore, it is still unclear if the 
relationship between cancer and retrotransposition in epithelial cancers is due to cancer 
activating the process of retrotransposition or due to retrotransposition causing somatic 
mutations which contribute to tumor formation.  Cancer is by no means a simple disease, in fact, 
it encompasses a wide-ranging group of more than 200 diseases that involve uninhibited 
proliferation of cells leading to tumor formation, in addition to several additional common 
features (211,212).  Epidemiological studies on twins suggest that environment plays a much 
clearer role in the process of tumorigenesis than genetics (213,214).  For example, Sorenson and 
colleagues found that when an adoptive parent died as a result of cancer before the age of 50, the 
rate of mortality due to cancer for the adoptees increased (214).  These findings suggest that a 
strong enough environmental mutagen will have a potent effect on individuals who live in the 
same environment despite differences in genetic background.  Furthermore, another study found 
that the overwhelming contributor to cancer development in twins was the environment (213).  
The authors found that even when they considered cancer for which there was statistically 
significant evidence of cancer heritability, most twin pairs were discordant for presence of the 
cancer (213).  Environmental factors contribute to sporadic cancer occurrence as much as 58-
82%, as compared to the highest known genetic contribution to cancers, colorectal, breast, and 
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prostate cancers which is 27-42% (213).  Differentiating between mutations which contribute to 
cancer development, referred to as drivers, and those which accumulate due to the dysregulation 
of DNA replication and repair pathways, dubbed passengers, is a continuous challenge in the 
study of cancer genetics.  The apparent dysregulation of L1 elements in cancer is only one of 
many sources of genetic aberrations that frequently contribute to cancer development.  However, 
L1 elements and other retrotransposons have a large size effect upon insertion and due to their 
structure have multiple ways in which their newly acquired presence can disrupt gene expression 
and regulation.  It is also telling that L1 mobilization has been observed in many different tumors 
(Doucet-O’Hare et al., 2015; Ewing et al., 2015; Helman et al., 2014; Lee et al., 2012; Rodić et 
al., 2015; Shukla et al., 2013; Solyom, Ewing, Rahrmann, et al., 2012b; Tubio et al., 2014), 
cancer cell lines (25,215,216), and during development (217–219).  Due to the potentially 
substantial effect of an L1 insertion and the predominantly deleterious effects on host gene 
expression observed thus far (205,220,221), L1 insertions may be more prone than other types of 
mutations to have an impact on tumorigenesis.   
There are many carcinogenic environmental factors (222) which have an impact on 
retrotransposon activity in cultured cells (223).  Benzoprenes, for example, are a risk factor for 
lung cancer, colorectal cancer, and breast cancer (224–226) and have been shown to increase L1 
retrotransposition in HeLa cells (227).  Exposure to certain metals such as cadmium, chromium 
VI, and nickel are risk factors for lung and breast cancer (228,229) and interestingly, nickel has 
been shown to induce a higher rate of L1 retrotransposition (230).  Another feature of many 
tumors is a higher level of free radicals involved in oxidative stress (231) and oxidative stress has 
also been demonstrated to affect L1 activity (232).  Furthermore, oxidative stress and DNA 
damage frequently occur as a result of cellular senescence and can also increase both 
23  
 
retrotransposition rates and chromosomal instability thereby potentially contributing to somatic 
mosaicism and cancer development (233–235).  It is certainly plausible that many more 
environmental factors which contribute to cancer development also activate L1 retrotransposition 
and thereby increase the probability of L1 generating an insertion which affects an oncogenic 
locus and contributes to tumorigenesis (236).   
When a cancer genome is sequenced tens or hundreds of thousands of single nucleotide 
variants, insertions, deletions, translocations, rearrangements, and other mutations may be found. 
In order to understand the role L1 mobilization plays in tumorigenesis, it is necessary to separate 
the winnow from the chafe, determine whether any somatic L1 insertions are present in the 
tumor, and absent from the normal tissues.  To determine whether or not somatic insertions are 
contributing to tumor development, the insertions must be mapped in individuals with relevant 
disease.  In 1992, Miki et al. mapped a somatic L1 insertion in a colorectal tumor in an exon of 
the APC gene (237).  The somatic insertion was confirmed with Southern blot and because APC 
is the primary tumor suppressor gene in colorectal cancer and causes familial adenomatous 
polyposis (238,239) it is reasonable to conclude that the somatic L1 insertion, which was found 
to be absent from normal colon, was sufficient to drive oncogenesis (236).  Although the 
preliminary discovery of an L1 insertion contributing to cancer occurred in the early 90s, it was 
two decades before researchers returned to the topic to investigate the role of L1 in 
carcinogenesis.  To date, only one other definitive somatic insertion has been found in the exon 
of a tumor suppressor gene.  An insertion into an exon of the PTEN gene was discovered with 
whole genome and whole exome sequencing by Helman and colleagues in 2014 (210).  High-
throughput next-generation sequencing enabled researchers to examine the genomes of more 
individuals at one time and compare those genomes between the cancer and normal samples in 
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addition to comparing individuals’ genome differences.  Due to the new technology available, 
many methods were subsequently specifically developed for assessing L1 activity in the genome, 
for detailed reviews see (240,241).  Prior to a paper from Iskow and colleagues, several groups 
were able to successfully identify novel L1 insertions; however, they used assays which were 
inherently low-throughput and which had high false positive rates (105,242,243).  The initial 
high-throughput method utilized for the discovery of somatic insertions, termed ‘Transposon-
seq’ utilized digested genomic DNA using restriction enzymes which recognize the 3’ end of the 
L1 and Alu elements (244).    The authors linked adapters to the resulting fragments and 
amplified them with PCR to create retrotransposon specific libraries (244).  In the initial efforts 
of the study, 38 ethnically diverse humans and 8 ATCC cell lines derived from human tumors 
were utilized to create libraries (244).  Approximately 4600 library fragments were cloned and 
sequenced with ABI capillary sequencing yielding 152 putative novel L1 insertion 
polymorphisms (244).  In order to ensure a low false positive rate, the authors applied 
specialized informatics to filter the datasets and identified high probability L1Ta insertion 
candidates (244).  The PCR validation rate for the insertions was 97% with approximately a third 
of the insertions possessing a minor allele frequency (MAF) equal to or below 5% (244).  
Additionally, 47 ‘rare’ insertions were found in very few individuals and 9 of them were only 
found in one cell line evaluated (244).  One of the nine rare insertions in only one cell line was 
deemed as a somatic insertion due to its presence in the tumor cell line and its absence from the 
normal cell line (244).  After finding the somatic insertion, the authors implemented their 
technique in a high-throughput fashion by acquiring 20 non-small cell lung cancers with matched 
normal tissues.  Previous work in the mouse brain (245) and in human neural stem cells (Coufal, 
Garcia-Perez, Peng, Yeo, Mu, Lovci, Morell, Oâ Shea, et al., 2009) suggested that L1 activity in 
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the brain was highly active. Two types of brain tumors were also evaluated in the study including 
glioblastoma and medulloblastoma (244) with 5 cases of each condition along with matched 
blood leukocyte controls (244).  The high-throughput version of ‘Transposon-seq’ utilized 
barcoding sequences to assign a given sequence to specific samples within the sample pool 
sequenced with 454 pyrosequencing (244).  Following sequencing analysis, 1389 distinct L1 
insertions were detected in the 30 samples assessed.  After all the novel insertion candidates were 
compared to the human reference genome and to dbRIP (107), 650 putative novel L1 insertions 
remained, and 45% of them had MAFs less than or equal to 5%.  Of all the individuals evaluated, 
93% of the genomes had at least one rare L1 insertion present in only a single human in the 
study.  After screening the low frequency alleles with PCR assays, the authors found there were 
9 tumor specific somatic L1 insertions present in their lung cancer cohort.  Surprisingly, no 
somatic insertions were confirmed in the brain tumors evaluated.  In six of the 20 lung tumors 
studied, somatic tumor-only insertions were confirmed.  Lastly, the authors confirmed 
hypomethylation of many potentially active polymorphic L1 elements in the genomes of affected 
patients (244).  The hypomethylation present in the affected individuals suggests that one 
mechanism of L1 escape from host control in cancer is due to changes in methylation due to 
mutations in tumor suppressor genes.   
Several years later, Lee et al used a computational method, ‘Tea’ for transposable 
element analyzer, to analyze whole genome paired end sequencing data from tumors and 
matching blood samples (Lee et al. 2012).  In this study, the authors performed a single 
nucleotide resolution analysis of retrotransposons in 43 high coverage whole-genome sequencing 
data sets from five cancer types (Lee et al. 2012).  The study samples consisted of colorectal 
tumors, ovarian tumors, prostate tumors, blood cancer, and brain cancer (Lee et al. 2012).  The 
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authors identified 194 high-confidence putative somatic retrotransposon insertions in the samples 
of epithelial origin only, e.g. ovarian, prostate, and colorectal tumors (Lee et al. 2012).  Of the 
194 high-confidence putative insertions, 183 of them were purported to be L1s, 10 Alu elements, 
and 1 endogenous retrovirus (ERV) (Lee et al. 2012).  It was later determined that the putative 
ERV insertion was likely caused by a microhomology-mediated break-induced repair mechanism 
(247).  With regard to the PCR and capillary sequencing validation of the predicted somatic 
insertions, 25/26 insertions were validated in colorectal cancer and 13/13 insertions validated in 
ovarian cancer with an overall rate of 97% validation (Lee et al. 2012).  Finally, the authors 
noted that somatic and germline L1 insertion sites differed in genomic distribution as well as 
epigenetic characteristics.  When comparing germline insertions to somatic insertions, germline 
events are depleted from genes significantly, likely due to strong negative selection on the events 
(248).  The authors assert that the retrotransposon insertions seem to provide a selective 
advantage in certain individuals and that the insertions occurred in genes commonly mutated in 
cancers and substantially disrupted their expression (Lee et al. 2012).   
In a publication from our own group in the same year, two high-throughput sequencing 
techniques which enrich for retrotransposons in different ways were utilized.  L1-seq, developed 
by Adam Ewing (249), utilizes a hemi-specific PCR based library construction method to enrich 
for the young, active subfamily of L1s in the genome.  RC-seq (version 1), developed by the 
Faulkner lab (220), uses probes designed to bind the 5’ and 3’ ends of L1 and SVA elements and 
probes tiled across the full length of an Alu.  The probes are tiled on an array and the sheared 
genomic DNA is applied to the array as the relevant sequences bind.  This DNA later has 
adapters ligated to it and is minimally amplified with PCR using only 8 cycles (220).  Using L1-
seq on two cohorts of 16 total colorectal cancer patients with matched tumor and normal tissues, 
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26/40 and 37/51 high stringency somatic insertions were identified and validated respectively.  
An additional 9 out of 16 lower stringency insertions with lower read-counts and map scores 
were identified and validated between both cohorts as well.  In total, L1-seq resulted in the 3’ 
validation of 69/107 putative tumor-specific somatic insertions and both 5’ and 3’ validation of 
35 of said insertions.  As is typical of both previous and follow-up studies, one tumor had 17 
insertions present while 3 others had no insertions.  Most of the insertions identified had severe 
5’ truncation and averaged about 1kb in size.  Five of the 16 colorectal cancer patient samples 
were barcoded, pooled, and analyzed by shallow, multiplexed RC-seq.  Using RC-seq, 8 L1, 83 
Alu, and 5 SVA somatic insertions different from those identified with L1-seq were predicted.  
Only one of the L1 insertions predicted was confirmed to be truly tumor-specific, and 11 high-
confidence predicted L1 insertions identified by L1-seq were also identified with RC-seq.  Of the 
remaining putative insertions, 6/8 L1s, 30/57 Alu elements, and 6/11 SVA elements were 
validated in both tumor and paired normal tissue.   
A year later, Faulkner and colleagues published an updated version of RC-seq which was 
utilized to analyze retrotransposon activity in 19 hepatocellular carcinomas (HCC) (205).  The 
HCC cases consisted of fresh frozen tissue from patients positive for HBV or HCV and matched 
normal tissue.  In the new version of RC-seq, a liquid phase capture was utilized to increase the 
number of probes available for binding to increase efficiency; furthermore the sequences of the 
probes used were also refined and edited to be a more effective pool for binding active elements.  
The optimized version of RC-seq produced a 4-fold increase in reads which aligned to non-
reference genome L1s per library sequenced.  Twelve out of 17 potential somatic insertions were 
validated in tumor only with PCR and sequencing confirmed the L1 is active in HCC.  No SVA 
or Alu element somatic insertions were confirmed in any of the patients; however, a single L1 
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insertion was confirmed in normal liver and was found to absent from the corresponding tumor.  
The insertion into normal liver is surprising because it had been previously assumed that 
retrotransposition was not an active process in somatic tissues with the exception of the brain 
(219–221,250).  If somatic retrotransposition happens in the normal tissues of some individuals, 
it is possible that in those individuals it could cause mutations which lead to disease like cancer 
development.  Interestingly, the authors noted three different germline insertions into the MCC 
gene, mutated in colorectal cancers, in three individuals with HCC.  The germline insertions 
coincided with a strong inhibition of MCC as confirmed with immunoblot and qRT PCR.  
Although this study did not definitively address whether or not somatic insertions contribute to 
tumorigenesis, it did present evidence that in some individuals inherited polymorphic L1 
insertions may play a role.  It seems plausible to assume that if a germline insertion can cause 
such a reaction, then so too can a somatic insertion.  
In 2014, yet another pipeline emerged for analyzing whole genome sequencing data from 
200 tumor samples and their matched normal counterparts (210).  The following cancers were 
analyzed in the study: lung adenocarcinoma, lung squamous cell carcinoma, ovarian carcinoma, 
rectal adenocarcinoma, colon adenocarcinoma, kidney clear-cell carcinoma, uterine corpus 
endometrioid carcinoma, head and neck squamous cell carcinoma, breast carcinoma, acute 
myeloid leukemia, and glioblastoma multiforme (210).  The study identified 7,724 unique, non-
reference germline insertion sites and approximately 65% of them are known retrotransposon 
insertion polymorphisms (RIPs) previously identified in other studies (108,207,244,249,251–
253).  In total 810 putative retrotransposon insertions were predicted in the cancer samples and 
absent from normal samples.  The candidate insertions exhibited the hallmarks of TPRT 
including target site duplications averaging 15 nucleotides in addition to a canonical 
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endonuclease motif (34,254).  However, forty-seven putative somatic retrotransposition events 
were selected for experimental validation.  The 47 tested insertions were predicted across 21 
individuals and four tumor types.   Thirty-nine of the insertions (83%) were validated as tumor 
specific by PCR and sequencing of either the 5’ or the 3’ end.  For 32 of the 47 insertions, 
evidence was present for both the 3’ and 5’ ends.  Two of the putative somatic insertions were 
found to be germline, present in both tumor and normal, after the validation attempt.  Six of the 
47 putative somatic insertions were not amplified in either the normal or the tumor samples.  Not 
unlike previous similar studies, it was noted that 97% of the L1 somatic insertions are in the 
L1Hs subfamily.  After considering which cancers exhibited L1 activity among their samples the 
authors noted that cancers of epithelial origin were the only ones which had detectable somatic 
retrotransposition events.  Historically, nearly all cancers found to possess retrotransposon 
activity, in the form of newly acquired somatic insertions unique to the tumor, have been 
epithelial cancers.  Interestingly, the authors also observed several 3’ transduction events from 
different regions of the genome in a single patient.  The 3’ transductions are evidence that at least 
three different source L1 elements contributed to the somatic insertions in the cancer.  In contrast 
to this finding, the authors also noted a patient in which a single L1 element caused at least 4 
events, detected due to their 3’ transductions, into different areas of the genome.  These findings 
seem to suggest two models for somatic retrotransposition activity in cancer.  In some patients, a 
single hyperactive source element may insert itself into multiple genomic locations in the same 
tumor.  In others, there may be several active source elements which contribute the somatic 
insertions present in the sample.  It is also possible that both of these situations happen 
simultaneously in the same individual as well.    
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Later in 2014, a paper analyzed whole-genome sequencing data on 290 tumor and 
matched normal pairs consisting of 210 primary tumors, 52 metastatic tumors, and 28 cancer cell 
lines with matched normal cell lines (202).  The samples were obtained from 244 patients across 
12 cancer types including: bladder, bone, breast, colon, head and neck, lung, pancreatic, prostate, 
and renal cancer as well as mesothelioma, melanoma, and glioma (202).  The algorithm used to 
analyze the sequencing data, “TraFiC’, identified 2,756 putative L1 retrotransposition events 
including both ‘solo’ L1 events and 3’ transductions.  PCR validation was attempted on 308 
putative insertions and 259 insertions were confirmed with PCR and capillary sequencing (202).  
The authors also observed a single patient with 22 somatic 3’ transduction events from a hyper-
active L1 which mobilized many times in the same cancer (202).  The average insertion length 
was approximately 1 kb for insertions lacking a 5’ inversion, the TSDs averaged between 10 and 
20 base-pairs, and 3’ transductions occurred in one fourth of the cancer genomes evaluated 
(202).  Due to the abundance of 3’ transductions in many of the samples, the authors were able to 
conclude that few loci were driving the 3’ transductions in cancer (202).   
Recently, another paper analyzing whole-genome paired-end sequencing was published 
in which the authors studied 43 cases of esophageal adenocarcinoma (255).  The authors 
predicted an average of 16 insertions per tumor and a range of 0 to 153 insertions among the 
patients studied (255).  One fifth of the L1 insertions found was predicted to have 5’ inversions 
and there were 9 insertions identified with 3’ transductions.  The authors also attempted to 
correlate p53 loss with L1 activity by evaluating p53 mutations in all of the patients.  The authors 
observed a p53 mutation present in over 88% of patients with esophageal adenocarcinoma 
patients studied; furthermore, two of the 5 cases where no p53 mutation were present were cases 
with no insertion (255).  In addition, it is noted that it is not possible to conclude that the L1s are 
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only active in the tumor as the technique is not sensitive enough to detect potential events in the 
non-cancer cells due to their potentially highly polyclonal nature (255).  A serious deficit in this 
study was the lack of matched normal tissues for nearly all patients.  Without matched normal 
tissue, it is impossible to know whether putative somatic insertions detected in the cancer are 
truly somatic or if they occurred in early development and are present throughout the tissue of 
interest.   
Using a technique dubbed ‘Tip-seq’, Rodic and colleagues studied 20 cases of pancreatic 
ductal adenocarcinoma (PDAC) to detect somatic L1 insertions present in the cancer and absent 
from normal pancreatic tissue (208).  The authors had previously described L1 protein ORF1 
expression in up to 89% of PDAC patients (256).  Tip-seq is a PCR based L1 enrichment library 
preparation technique and it detected 268 somatic L1 insertions in the tumors of 18 patients 
evaluated which were absent from matched normal tissue (208).  A range of 0 to 65 insertions 
was detected in the patients and an average of 15 insertions per case was calculated (208).  There 
were 15 metastases which were evaluated with Tip-seq as well from 15 different patients and 
242 insertions were detected in these samples (208).  In 13 of the cases where both a metastasis 
and a primary tumor from a patient were shared, 45 insertions were confirmed by PCR and 
capillary sequencing to be present in both tissues and absent from the normal tissue (208).  The 
expression of ORF1p in the samples subjected to Tip-seq correlated with the number of 
somatically acquired insertions per sample (208).  The authors reported 81% of tested insertions 
validated with both PCR and capillary sequencing with all insertions being 5’ truncated and an 
average size of approximately 1 kb (208).  Finally, the authors noted two 3’ transductions among 
the validated insertions in the study (208).   
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Ewing et al. published a study looking at multiple types of cancer including 4 colorectal 
cancer patients with matched colonic polyps and normal colon, 7 patients with pancreatic ductal 
adenocarcinoma with matched normal, 7 patients with gastric cancer and matched normal tissue, 
and 8 testicular germ cell tumors with matched blood (204).  For 8 of the aforementioned cases, 
metastatic tissues were available and evaluated as well (204).  Following L1-seq (249) and 
subsequent computational analysis 104 somatic heterozygous L1Hs insertions were validated by 
PCR and Sanger sequencing in the 18 gastrointestinal cancers and 1 insertion was validated in a 
single patient with a testicular germ cell tumor (204).  However, the most interesting finding in 
this article was insertions occurring in the polyps which precede the cancer development (204).  
This pattern suggests that L1 is active in tissue before the cancer develops and certainly makes it 
seem more likely that L1 could contribute to the process of tumorigenesis.   
All of the cancer studies performed to date have strongly established the hyper-activity of 
L1 in epithelial cancer; furthermore, many of the studies have established similar patterns with 
regard to retrotransposition.  Several of the studies noted an average insertion size of 
approximately 1 kb likely due to the dramatic 5’ truncations which most of the validated 
insertions possess(202,206,208).  Thus far, nearly all the papers have reported target-site 
duplications in the same size range, approximately 10-20 nucleotides on average, and 
approximately 20% of the insertions detected in cancer have 5’ inversions.   
Although the activity of L1 elements in cancer has been firmly established and the events 
seem to adhere to most of the hallmarks of the process, it is still uncertain to what degree these 
elements play a role in carcinogenesis.  Anything short of a glaringly obvious insertion 
disrupting a known tumor suppressor or activating an oncogene is a difficult sell to the scientific 
community as a cause or contributor to cancer.  Furthermore, there is the possibility that the 
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dysregulation of normal cellular processes in cancer may simply be enabling L1 activity due to 
differences in methylation or the under expression of host genes which normally suppress 
retrotransposons activity.  The evidence contrasting the simple activation of elements due to 
cancer development is the confirmed somatic insertions in not only the precursor conditions to 
cancer, but also in normal tissues.  Observations of validated somatic insertions in tissues which 
are the precursor to cancer were made in the recent publication by Ewing and colleagues and 
have also been observed in work which will later be discussed thoroughly in this dissertation.  
Although there is mounting evidence of somatic retrotransposition occurring in normal tissues, it 
has not been definitively shown that this activity leads to cancer.  Like any other potential 
mutagen, retrotransposition likely leads to disease a certain percentage of the time regardless of 
the disease type.  However, when retrotransposons are hyper-active in a tissue, like in cancer or 
potentially precancerous conditions, it may be more likely to be the cause of a mutation which 
leads down the path to cancer development.  In the future, to distinguish between 
retrotransposons as passengers verses drivers, single cell sequencing and the acquisition of a 










Areas of Study 
The chapters which follow describe the utilization of an established technique to detect 
somatic L1 insertions occurring in cancer, in addition to the optimization of ORF1p detection via 
IHC in multiple types of cancer and normal tissues.  This thesis will cover two distinct projects 
on esophageal adenocarcinoma and esophageal squamous cell carcinoma respectively, which 
characterize the activity of endogenous retroelements in both pre-cancerous conditions and 
cancer.   
In Chapter 2, I describe the first of the two projects in which I utilized L1-seq (249) to 
evaluate the level of retrotransposition occurring in patients with Barrett’s esophagus and 
esophageal adenocarcinoma.  The subjects in the study consisted of 5 patients with benign (non-
progressive) Barrett’s esophagus, 5 patients with Barrett’s esophagus which progressed to 
esophageal adenocarcinoma, and10 additional esophageal adenocarcinoma patients (206).  Not 
only did I evaluate the insertions present in the tissues of the patients, but I also looked at ORF1p 
expression in many of the normal and cancer tissues (206).  Interestingly, I observed mild 
ORF1p expression in many of the normal esophageal tissues evaluated from patients; however, 
the ORF1p expression was higher in the cancer samples.  Furthermore, I observed sub-clonal 
insertions which were present in only a few cells in the normal tissue or the pre-cancerous tissue 
and then were expanded in the resulting lesion(206).  This work was recently published in the 
Proccedings of the National Academy of Sciences (206). 
In Chapter 3, I describe my second project, using L1-seq (249) to examine the L1 
retrotransposon activity and ORF1p expression in nine patients with esophageal squamous cell 
carcinoma (Doucet-O’Hare et al., in prep).  In these samples, I was able to observe more than 74 
retrotransposition events where 12 events appeared to be sub-clonal in normal esophagus and 
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clonal in esophageal squamous cell carcinoma (Doucet-O’Hare et al., in prep).  These data will 
be compiled into a publication for Oncogene and submitted in the coming weeks.   
In Chapter 4, I will outline future directions for the areas of study which are discussed 
herein.  The activity of L1 retrotransposons in cancer genomes is fairly well characterized; 
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Barrett’s esophagus (BE) is a common disease in which the lining of the esophagus 
transitions from stratified squamous epithelium to metaplastic columnar epithelium that 
predisposes individuals to developing esophageal adenocarcinoma (EAC).  We hypothesized BE 
provides a unique environment for increased L1 retrotransposition.  To this end, we evaluated 5 
patients with benign BE, 5 patients with BE and concomitant esophageal adenocarcinoma 
(EAC), and 10 additional patients with EAC to determine L1 activity in this progressive disease.  
After L1-seq, we confirmed 118 somatic insertions by PCR in 10 of 20 individuals.  We 
observed clonal amplification of several insertions which appeared to originate in normal 
esophagus (NE) or BE and were later clonally expanded in BE or in EAC.  Additionally, we 
observed evidence of clonality within the EAC cases: specifically, 22 of 25 EAC-only insertions 
were present identically in distinct regions available from the same tumor suggesting that these 
insertions occurred in the founding tumor cell of these lesions.  L1 proteins must be expressed 
for retrotransposition to occur; therefore, we evaluated the expression of ORF1p, a protein 
encoded by L1, in 8 of the EAC cases for which formalin-fixed paraffin embedded tissue was 
available.  With immunohistochemistry, we detected ORF1p in all tumors evaluated.  
Interestingly, we also observed dim ORF1p immunoreactivity in histologically normal 
esophagus of all patients.  In summary, our data show that somatic retrotransposition occurs 
early in many patients with BE and EAC, and indicate that early events occurring even in 







Gastroesophageal reflux disease (GERD) affects a large proportion of Western 
populations and represents a significant healthcare burden partially due to its frequent evolution 
into Barrett’s esophagus (BE) (257).   BE was first described by Norman Barrett in 1950 (258) 
and is a common disease in which the lining of the esophagus transitions from stratified 
squamous epithelial cells to a cancer predisposing metaplastic columnar epithelium (258). The 
transdifferentiation increases cellular resistance to the low pH from the acid entering the 
esophagus through the sphincter separating it from the stomach (259).  BE occurs in 8% to 20% 
of patients with GERD or about 3-8% of the total population (259).  Furthermore, recent studies 
suggest that another 3-8% of the general population may have BE without symptoms (259).  
 The risk of a patient with BE developing the advanced premalignant lesion, high-grade 
dysplasia, or frank esophageal adenocarcinoma (EAC) is 0.5% per year; however, the five-year 
survival rate from EAC is only 13%-16% (259).  Moreover, although the risk of malignancy is 
low, an EAC diagnosis is not usually made until the late stages of the disease when the illness is 
nearly incurable (259,260).  Early diagnosis of dysplasia and EAC can be accomplished in 
patients with BE by screening endoscopies with biopsies performed at regular intervals 
determined by the physician (260).  Due to the availability of tissue from these biopsies, 
detecting how the disease progresses and tracking clonal populations throughout disease 
progression has provided valuable insights into early cancer development (261,262).   
Various types of mutations can be detected and subsequently monitored by biopsy to 
determine which clonal population of cells progresses to cancer.  One source of mutation in 
epithelial cancer is retrotransposition (201–203,205,210).  Retrotransposons compose 
approximately 45% of the human genome (111) and are mobilized via an RNA intermediate to 
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new genomic locations.  The Long-INterspersed Element 1 (LINE-1 or L1) is the only 
autonomous retrotransposon that encodes the proteins necessary for mobilization and reinsertion 
into the genome.  The two proteins encoded by L1 are responsible for the mobilization of other 
types of retrotransposons, Alu and SVA, as well as processed pseudogenes(31,48).  Aside from 
contributing to genomic variation, retrotransposons can also have functional impact by inserting 
into transcription factor binding sites, donor and acceptor sites involved in mRNA splicing, 
enhancer sites, or protein coding regions of genes.  To date, there are over 100 known 
retrotransposon insertions that caused single-gene diseases (110,111,193,263,264).   
L1 mobilization in epithelial cancer has been observed by many groups at both the 
protein and DNA level.  Interestingly, each individual has a different complement of 80-100 
potentially active L1 elements in their genome which partially explains the large variation of 
somatic insertions detected in previous studies (201–203,205,210,249).  Although it is evident 
that L1 is active and expressed in many cancer types, this activity has not been robustly 
evaluated in pre-cancerous lesions such as BE.  New somatic insertions of L1 in BE could be 
used to track clonal progression of disease. 
We hypothesized that the alterations in the esophageal lining as it undergoes cellular 
transdifferentiation present a permissive environment for retrotransposition.  To test this 
hypothesis we evaluated individuals with BE who progressed to EAC, as well as those with non-
progressive benign BE.  We determined the occurrence of retrotransposition in these patients 
using L1-seq, a high-throughput L1-targeted sequencing method (20), and validated 118 somatic 
insertions in 10 of the 20 patients evaluated (Fig 2.1).  Substantial levels of L1 protein expression 
were also detected in the EAC with immunohistochemistry; moreover, the protein was detected 
in the normal esophageal (NE) tissue of all patients tested.  We conclude that this high 
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prevalence of L1 activity and insertions in BE and EAC, taken together with previous findings in 
other epithelial cancers, suggests a strong link between cancer and L1 activity.  However, it is 
uncertain to what extent the dysregulation of normal cellular processes is contributing to L1 
activation in cancer, as well as whether these somatic insertions are contributing to 







Figure 2.1: Distribution of reference, non-reference, and validated L1 somatic insertions in NE, 
BE, and EAC. A) Circos diagram mapping the distribution throughout the human genome of 20 
validated high-stringency insertions in BE only (inner red circle), the 765 low stringency 
reference (outer green circle) and 218 polymorphic insertions (orange circle) detected with L1-
seq. Group contains 5 individuals.  B) Circos diagram mapping the distribution of the predicted 
23 high stringency insertions in BE only (yellow circle), 3 BE and T (orange points), and 23 T 
only (Red circle) as well as the low stringency reference (752) and polymorphic (218) insertions 
detected with L1-seq (green and orange respectively). Group contains 5 individuals. 
C) Circos diagram mapping the distribution of 49 predicted high stringency insertions in tumor 
only (red circle), 537 low stringency reference (green circle), and 282 low-stringency 
polymorphic (orange circle) insertions.  The final group contains 10 individuals.  The somatic 
insertions (e.g. all insertions that are not reference and polymorphic insertions) are predictions 
and are therefore restricted by sequencing read counts of 100 reads or greater; however, the 
reference and polymorphic insertions have been previously published and are more common in 
the population and are therefore restricted only by a sequencing read count of 25 or greater and a 
map score of 0.5 or larger.  For the Esophageal cancer group, our map scores were lower overall 
for the reference insertions; therefore, we restricted these insertions by a read count of 20 and a 








L1-seq:  DNA was isolated from the frozen tissue samples, from thinly sliced sections of 
tissue embedded in OTC freezing media with the DNeasy kit (Qiagen).  Our samples were not 
micro-dissected to remove all normal tissue largely because half of our samples were either 
acquired as genomic DNA or previously frozen tissues.  Equal amounts of genomic DNA from 
each individual were pooled by group.  Hemi-specific PCR amplified the young, active L1 
elements from the genome (249).  Products between 200 and 500 sBowtie2, the alignments 
sorted based on presence or absence of L1 sequence, and the reference insertions and previously 
published polymorphic insertions were identified (249). Our bioinformatics analysis was 
essentially identical to previous analyses (249). 
Stringency Analysis:  For an insertion to be considered “high-stringency” in the library 
containing matched EAC and NE samples, we required at least a map score of 0.5 or greater, 50 
total reads, and a window of 100 base-pairs or more spanning the junction of the 3’ end of the L1 
and the genomic DNA.  Low-stringency insertions had below 50 reads, a map score of 0.5 or 
greater, and a window of less than 100 base pairs.  These original parameters are similar to those 
previously used (249); however because we had more difficulty validating insertions in our other 
libraries we reevaluated the thresholds.  For both of the remaining libraries: 1) the library 
containing the matched BE and NE samples and 2) the library containing matched EAC, BE, and 
NE samples we adjusted the thresholds by looking at the few validated insertions from the 
original high-stringency group. We noted the lowest unique read count, total read count, and 
window size among the previously validated insertions in each group, and used these numbers as 
our new parameters for high-stringency.  We also required a higher map score for the redefined 
high-stringency insertions in both libraries. Consequently, a high-stringency insertion in the 
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library containing matched BE and NE samples required a map score of 0.8 or greater, 3 unique 
reads, 64 total reads, and a window of at least 107 base-pairs. High stringency insertions in the 
library containing matched EAC, BE, and NE samples required a least a map score of 0.8, 3 
unique reads, 63 total reads, and a window of 140 base-pairs.  For each insertion validated, the 
specific map score, read count, unique read count, and window size (bp) is noted (Table S3).  
Random Insertion Selection:  For the group of matched NE and EAC samples, 
insertions were randomly selected using a random number generator with parameters for both 
high and low stringency.  A list of random numbers between 1 and the total number of predicted 
insertions (at varying levels of confidence) was then created and the rows which matched the 
numbers generated in the “.csv” file containing the predicted somatic insertions were selected for 
validation with PCR and sequencing.  We made a histogram of the data to be sure the selection 
was even and random throughout the number range given and finally performed an empirical 
distribution analysis to evaluate our random selection process.    
Immunohistochemistry: Immunohistochemistry was performed using the EnVision 
System-HRP (Dako; catalog K4006) according to the manufacturer’s protocol. Primary antibody 
incubation was performed using the mouse monoclonal ORF1 (1.25 mg/ml) at a 1:3000 dilution 
for 40 min at room temperature.  Secondary antibody incubation was performed per 
manufacturer protocol.  For the skin biopsy, the sample was stained in an overnight protocol at a 
1:1200 dilution with the monoclonal mouse ORF1 antibody.  A second rabbit monoclonal ORF1 
antibody was used to confirm initial results. This second antibody was used at a concentration of 
1:2000 dilution with an overnight incubation at 4ο C and secondary antibody incubation as per 
manufacturer protocol. Orf1 monoclonal mouse antibody recognizes amino acids 35-44 while the 
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rabbit monoclonal antibody (JH74) detects the coiled-coil domain including amino acids 137-





















BE patients without cancer 
To estimate the pervasiveness of retrotransposition in BE, we studied 5 patients with BE 
who did not develop high-grade dysplasia or EAC for at least 15 years after their BE specimens 
were obtained.  If L1 is active in patients without cancer this finding would suggest that the 
cellular environment in BE per se is permissive for retrotransposition.  We obtained matched 
DNAs from white blood cells (WBC), NE, and BE and performed L1-seq to enrich DNA 
libraries for L1 insertions, then subsequently identify those insertions unique to the metaplasia 
(20).  We classified these “somatic insertions” as those present only in a subset of cells and not 
inherited from a previous generation, e.g. insertions unique to BE but absent from matched NE 
and WBC DNA.  Alternatively, we reasoned that somatic insertions could occur in a few normal 
squamous esophageal cells that became clonally amplified in BE.  To confirm that an insertion 
was truly absent, we performed nested PCRs on all samples (Fig 2.2). 
We confirmed a total of 20 insertions total in 4 of 5 patients evaluated by PCR and 
Sanger sequencing.  Of the 20 confirmed insertions, 11 were amplified easily with a single PCR 
(conventional), without the need for a secondary PCR using nested primers (Fig 2.2A).  We 
hypothesize that insertions which amplified with a conventional PCR were likely present in a 
large proportion of cells and therefore clonal.  One insertion in particular was amplified easily 
with a conventional PCR in BE DNA; notably, this insertion was also observed in normal 
esophageal DNA only after nested PCR but remained undetectable in WBC DNA (Fig 2.3A-B).  
We speculated that this somatic insertion could have initially occurred in a single normal 
squamous cell exposed to high acid content during episodes of GERD, which then 
transdifferentiated into columnar epithelium, and clonally expanded as BE.  This finding 
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suggests that L1 insertions occur in normal squamous esophageal cells at a low frequency and 
then become more easily detectable after they clonally expand in a disease such as BE or EAC, 






Figure 2.2: Somatic insertion validation process. (A) Diagram of the PCR validation scheme for 
putative insertions, the three prime end of the LINE-1 insertion is pictured adjacent to a poly A 
tail.  The nested empty site and filled site primers are flanking the empty and filled site primers.  
In a nested PCR, the nested primers are used in the first of two reactions. Two uL of product 
from the first reaction (with ES and FS primers) is used as template in a second PCR with the 
nested primers to amplify difficult or rare products.  (B) Two examples of validations for 
insertions present in only tumor and absent from normal DNA.  On the left, inside the red box, a 
PCR result depicting both the empty site (ES) and filled site (FS) products for both the normal 
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and tumor DNA samples from patient 11.  Only in the tumor is a filled site band present 
confirming the insertion is present in only the tumor DNA.  In the image on the right side on 
Figure 2B, a PCR depicting another validation of a somatic insertion present in BE and absent 
from normal esophageal and white blood cell DNA.  There is only a band present in the BE 
sample for the FS PCR; however, the ES PCR has bands for all three DNA samples as a positive 
control. (C) An insertion sequence with the unique genomic DNA(blue), target site duplications 
(purple), LINE-1 sequence (red), and the poly A tail sequence (orange). 
Figure 2.3: Gels showing clonal expansion of insertions originally present in NE.  A) 
The first of two nested PCRs done on 1014 WBC, 1014 NE, 1014 BE DNA, and with a water 
control (no DNA), attempting to amplify the “Filled site” or the insertion in all three samples.  
There is only a band present in the BE DNA showing the insertion is likely clonal in BE.  B) The 
second PCR or the “nested PCR” showing that with a nested PCR the insertion is present in 1014 
NE too.  C) The first of two nested PCRs done on 1099 NE, 1099 BE, 1099 T, and a water 
control (no DNA), attempting to amplify the “filled site” or the insertion in all three samples.  A 
band is present for the PCR on the tumor DNA showing the insertion is likely clonal in the 
tumor. D) The second or “nested” PCR showing that with nested PCR the insertion is also 
present in NE and in BE DNA.   
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BE patients with cancer 
After establishing that L1 is active in patients with benign BE, we evaluated individuals 
whose disease progressed to EAC.  We hypothesized that individuals who develop EAC would 
have as many or more somatic insertion events due to increased genetic instability in frank 
cancer (6).  We obtained samples from 5 patients with concomitant BE and EAC.   Genomic 
DNA was isolated from NE, BE, and EAC tissues resected concurrently.  After L1-seq we 
validated a number of these insertions in 2 of the 5 patients.  We amplified and successfully 
Sanger sequenced 11 of 12 tested insertions which occurred in BE tissue alone, 27 of 36 in EAC 
alone, and 3 insertions that occurred in both BE and matched EAC.  Due to the known 
polyclonal nature of BE, we had not expected all insertions detected in BE to be present in the 
matched EAC (262).  We reasoned that typically, only one clonal population of cells should have 
evolved into the tumor and thus retained mutations acquired in the precursor lesion; the 
remaining clonal populations in the BE would not be expected to contain these same mutations 
(262).    
The three insertions that were validated in multiple tissues provided a unique opportunity 
to look at the contribution of different clonal populations to the precursor lesion and the tumor.  
We observed three different stages at which a somatic insertion could occur. First, one of the 
insertions was detected without nested PCR in both BE and matched EAC; therefore, this 
insertion was likely part of a dominant BE clone which progressed to EAC.  The second 
insertion was readily detected in EAC but required nested PCR to be detected in BE.  Finally, a 
third insertion was amplified with conventional PCR in EAC, but was only evident in both NE 
and BE following nested PCR.  This third insertion likely occurred in an NE cell, which evolved 
into BE, and subsequently clonally expanded in the EAC (Fig. 2.3 C-D).   Altogether, these data 
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are further evidence that insertions occur at a low level in normal or metaplastic tissue and may 
later expand into a malignant clone.  Similar observations, insertions which are easily amplified 
in the cancer tissue but only amplified in normal tissue following nested PCR reactions, have 
been observed by others in our lab in gastric cancer. 
Similar to our previous group of non-progressive benign BE samples, only 2 of 5 
individuals had somatic insertions in either BE, EAC, or both tissues.  Although fewer patients 
had insertions in the matched BE-EAC group than in the group with BE or EAC alone, there 
were on average more somatic insertions validated in the patients with BE and EAC.  In 
individuals with BE alone, we observed an average 5 insertions per person (20 insertions divided 
among 4 patients) while in patients with EAC there were 23.5 insertions on average per person 
(47 insertions among 2 patients).  Because of the small sample size studied, it was impossible to 
determine whether this observed difference was statistically significant.  Nevertheless, the wide 
range in the number of insertions per patient and the frequency of patients with insertions is in 
agreement with other observations (201–203,205,210). 
EAC patients 
 To further investigate the activity of retrotransposons in EAC, we obtained samples from 
10 additional patients with fresh-frozen matched NE and EAC tissue samples.  Following L1-
seq, we confirmed 49 of 72 randomly selected, high-stringency insertions (Methods) with PCR 
and Sanger sequencing.  We then selected 20 low-stringency insertions (Methods) for validation 
and confirmed 6 additional somatic insertions.  These confirmed insertions occurred in 4 of the 
10 individuals’ samples with great variation among individuals regarding the number of somatic 
insertions. Extrapolating from this large number of low-stringency predicted insertions by L1-seq 
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and our observed 30% validation rate in this group, we speculate that the number of potential L1 
insertions per EAC is probably in the hundreds. 
Previously, others have shown variability with respect to the number of confirmed 
somatic insertions per person as well as the proportion of individuals harboring somatic 
insertions (201–203,205,210).  However, many studies have not thoroughly tested the potential 
clonality of the confirmed insertions.  We tested 25 of the confirmed insertions in up to 6 tissue 
sections (20 in 6/6 sections and 2 in 2/2 sections) (Figure 2.4).  We observed that 22 of these 25 
insertions appeared in all sections tested, while the remaining 3 insertions were present in 5/6 
sections tested (Figure 2.4).  When insertions exist in multiple tissue sections, it suggests that 
they are likely clonal and may have occurred early during tumorigenesis, or even in the precursor 
lesion (BE).   The concept of insertion clonality is important because it supports the conclusion 






Figure 2.4: Representative gels illustrating the presence of specific insertions in multiple 
sections of tumor tissue. FS refers to the filled site PCR while ES refers to the empty site PCR as 
in figure 2.2.  Two additional sections of each tumor were also tested and are not shown here.   
Characterization of BE and EAC specific insertions 
We established that retrotransposition is an active process in some BE and EAC patients 
by confirming 118 somatic insertions using PCR and Sanger sequencing.  The confirmed 
insertions did not display an obvious bias for chromosomal location (Figure 2.1).  In order to 
identify the precise insertion sites, we confirmed the 5’ ends of 35 of the somatic insertions.  For 
a subset of the insertions, we identified target-site duplications (TSDs) and endonuclease 
cleavage sites, both established hallmarks of retrotransposition (Table 2.1).  However, out of 24 
endonuclease cleavage sites identified, only 7 were similar (differed by two base pairs or less) to 
the canonical endonuclease site (111); the remaining 17 sites were more divergent from the 
canonical sequence.  Furthermore, 11 insertions lacked TSDs and clear endonuclease cleavage 
sites indicating they were likely endonuclease independent insertions (254).  Of the 11 insertions 
presumed endonuclease independent, 6 insertions had deletions at the site of integration (265).  
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Additional characteristics of these insertions, including mapping statistics of total read count, 
unique read count, and alignment windows, as well as genes nearby insertion sites are noted in 
Table 2.1. We observed variable lengths among the insertions for which we confirmed 5’ ends, 
ranging from 111 to 1,579 nucleotides (without the poly-A tail) with 29 of 35 insertions, 
measuring under 500 nucleotides (Table 2.1).  For the 21 of 35 insertions with TSDs, 12 were 
longer than 10 nucleotides (Table 2.1).  One insertion contained a 3’ truncated L1 element 
wherein 100 nucleotides of the 3’ end of the L1 were deleted from the insertion site suggesting 
internal reverse transcriptase priming (45).  Eleven of 35 insertions contained a 5’ inversion, 
consistent with previous reports (201–203,205,210). 
We did not confirm any insertions into exons in either BE or EAC; however, of the 118 
confirmed somatic insertions, 48 insertions were into intronic regions of 50 genes.  Twenty-three 
of these 48 insertions were into genes previously associated with cancer (Table S2).  Our 
findings show a statistically significant enrichment of insertions into genes previously associated 
with cancer (p value < 1e-10 by Fisher’s exact test).  In order to accurately test for the observed 
enrichment, we accounted for the sizes of all the genes into which insertions occurred as well as 
the size of all cancer genes in the genome and the probability that an insertion would hit more of 
those genes by chance alone.  After accounting for gene size, we still observed a significant 







































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 2.1: Somatic Insertion Characterization. All validated insertion locations noted in the 
table, along with TSDs, endonuclease cleavage sites, poly A tail length, and introns of genes into 
which insertions occurred. The asterisks denote samples in which insertions were detected only 






































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 2.2: Confirmed Somatic Insertion into Genes Associated with Cancer. Cancer genes into 
which confirmed insertions occurred, relevant references for cancer association, and entrez gene 
ID. NCG 4.0 column indicates whether or not the cancer gene is included in the network of 


















L1 Expression in NE and EAC 
Theoretically, retrotransposition is dependent on L1 protein expression for its activity; 
therefore, the genetic evidence of somatic insertions strongly suggests L1 proteins are expressed 
in precancerous lesions as well as cancer.  Expression of L1 protein has been observed in many 
cancer types previously but was only rarely detected in histologically normal tissue adjacent to 
the cancer (209,266,267).  Furthermore, the evidence of somatic insertions in normal esophagus 
suggests there must be at least transient or a low-level of L1 protein expression in the tissue.  
One of the two proteins encoded by L1, open-reading frame 1p (ORF1p), has been observed in 
many cancer types and has occasionally been observed in normal tissue adjacent to cancer 
(209,266,267).  To evaluate ORF1p expression in the patients harboring somatic L1 insertions, 
we obtained formalin-fixed paraffin-embedded (FFPE) tissues from 8 of the aforementioned 
EAC patients.  
We observed ORF1p expression in all 8 of these tumor samples by 
immunohistochemistry (IHC) (Table S3). The level of ORF1p expression varied among 
individuals as well as within individual tissue sections where cancerous glands were developing 
(Figure 2.5A-F). All of the samples with a confirmed somatic insertion showed ORF1p 
expression.  There was no correlation between protein expression and the number of confirmed 
somatic insertions per individual (Table S3).  Interestingly, we detected low level ORF1p 
expression in all 4 of the available matched normal tissues in both the stratified squamous 
epithelium and the smooth muscle (Figure 2.6A-F). Expression was absent from the progenitor 
stem cells of the stratified squamous epithelium and seemed to increase with cellular maturation 
as the cells increased their cytoplasm and radiated away from their progenitors.  The expression 
was absent from the submucosa of the tissue.  Expression was observed with two separate 
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monoclonal antibodies that detect different epitopes of the protein (209).  Although it was 
surprising to observe ORF1p expression in normal esophagus, it does support our finding of 
somatic insertions in normal esophagus that later expanding in subsequent metaplasia and/or 
cancer. 
To investigate whether the expression present in the normal esophagus was limited to 
patients who had concomitant cancer, we obtained one normal esophagus sample from a biopsy 
conducted on a patient with gastric ulcers.  We also obtained a normal skin biopsy to evaluate the 
squamous epithelium expression of ORF1p in an epithelial tissue.  In both the normal biopsies, 
dim ORF1p immunoreactivity was evident in the squamous epithelium of the tissue (Figure 
S1A-B).  LINE-1 expression in normal epithelial tissues, albeit at low levels, may allow for 
retrotransposition events. Perhaps a subset of somatic retrotransposition events reported in 
epithelial cancers actually occur prior to transformation (201–203,205,210).  At the same time, 
the higher levels of LINE-1 expression we see in these cancers may selectively promote somatic 







Figure 2.5: Representative photomicrographs depicting LINE-1 ORF1p immuno-labeling in 
esophageal carcinomas. A) Virtually no immuno-labeling identified with the primary LINE-1 
ORF1p antibody was not used in the IHC procedure (i.e. no antibody control) Final 
magnification x100 B) Same case as A, when incubated with LINE-1 ORF1p antibody, 
indicating the cancer is strongly reactive for ORF1p antigen. Final magnification x100 C) 
Virtually no immuno-labeling identified in the no antibody control. Final magnification x100. D) 
Same case as C, when incubated with LINE-1 ORF1p antibody, indicating the cancer is reactive 
for ORF1p antigen. Final magnification x100. E)-F) Two additional EAC cases which are 






Figure 2.6: Representative photomicrographs depicting LINE-1 ORF1p expression in normal 
esophageal tissue. A) and C) Normal esophageal tissue from two distinct individuals stained with 
H&E final magnification x100. B) Same case as A) when incubated with LINE-1 ORF1p 
antibody, indicating the normal esophageal tissue is reactive for ORF1p antigen. Final 
magnification x100. D) same case as C) when incubated with LINE-1 ORF1p antibody, 
indicated the normal esophageal tissue is reactive for ORF1p antigen. Final magnification x100. 
E) and F) Normal esophageal tissue from two distinct individuals showing the smooth muscle is 








Figure 2.7: ORF1p expression in normal esophagus and normal skin samples. A) Normal skin 
biopsy showing ORF1p expression localized in the stratified squamous epithelium. Final 
magnification x160.  B) Normal esophagus biopsy from patient with stomach ulcers showing 















Patient  Disease Level of Expression  Insertions Validated 
9 EAC ++ 0 
10 EAC + 7 
11 EAC ++ 40 
12 EAC + 1 
14 EAC + 0 
16 EAC ++ 0 
17 EAC + 1 
18 EAC + 0 
 
Table 2.3: Correlation between ORF1p expression and somatic insertions in EAC. Table 
displaying relationships between ORF1p expression and insertion occurrence in all subjects with 












Improved understanding of carcinogenesis should lead to earlier diagnosis and more 
effective treatment, but this advance requires the study of precursor lesions.  In many ways, BE 
is ideal for studying clonal expansion in precursor lesions even when disease progression does 
not occur. BE is accessible and present in a sizable proportion of the Western population, even 
though it only progresses to EAC in a small subset of patients (259).  Cellular processes that are 
dysregulated during the transdifferentiation from stratified squamous epithelium to metaplastic 
columnar epithelium may provide a fertile environment for dysregulation of L1. 
We found that retrotransposition is active in a subset of individuals with BE and EAC; 
however, this process does not occur in all patients and is active in patients with long-standing 
benign disease.  Therefore, L1 activity alone is not a reliable predictor of disease progression in 
BE.  BE appears to provide a permissive environment for L1 retrotransposition, which in turn 
increases the mutational burden and potentially contributes to disease progression.   As evidence 
of this permissive environment, we demonstrated that L1 elements were active in 6 of the 10 BE 
tissues evaluated by confirming 46 new somatic insertions.  Furthermore, we validated 75 
insertions in 6 of 15 EAC samples.  Where somatic insertions occurred, there was a variable 
frequency of events, ranging from 1 to 44 insertions, among different individuals.  In contrast to 
our previous colon cancer study (201), we did not observe a linear correlation between the 
number of insertions and any other characteristic, including age or L1 protein expression.  
Many of the insertions validated in BE and EAC had characteristics which differ from 
typical germline somatic insertions (51).  First, we observed 8 of 35 (23%) insertions with 
integration-site deletions, much greater than the 10% seen in the germline (111). Our failure to 
detect more than 30% of the 5’ ends may, in a number of the cases, be due to even larger 
74  
 
integration-site deletions (265).  Secondly, we found 11 insertions which appeared to be 
endonuclease independent, a much larger number than that observed in germline insertions 
(111,249).  These insertions were presumed to be endonuclease independent due to their lack of 
both target site duplications and clear endonuclease cleavage sites, both hallmarks of the 
canonical process of retrotransposition.  Thirdly, the majority of the insertions for which we 
identified the 5’ end were highly truncated with 29 of 35 below 500 nucleotides in length.  Also, 
we did not detect any 3’ transductions among our confirmed insertions in contrast to the findings 
of others (202), but L1-seq detects only a small fraction of these events. 
Somatic L1 insertions are seldom observed in normal tissues (221) with the most notable 
exception being those observed in the hippocampus (220,268).  Between our three groups of 
samples analyzed with L1-seq, we attempted to validate 9 high-stringency insertions predicted in 
normal esophagus only.  Even with nested PCR we were unable to confirm any of these normal-
only insertions, a result that we have seen previously for normal-specific insertions (203).  
Interestingly, we validated two insertions in normal tissue that were also present in BE and EAC. 
This finding suggests that at least some insertions may occur in normal squamous epithelium 
cells and are then selected for in the ensuing pathological state.  We speculate that indeed many 
of the BE and EAC insertions occur initially in only one or a small number of normal esophageal 
cells.  Clonal expansion in diseases such as BE and EAC may make it easier to detect the low 
level of L1 activity in a subset of normal cells. Future studies utilizing single-cell sequencing 
may allow us to better determine the activity of L1 in normal tissues and whether insertions in 
BE or in tumor are truly clonal.   
Somatic retrotransposition occurs at a detectable rate in squamous cell lung, head and 
neck, colorectal, endometrial, hepatocellular, breast, prostate, bone, and various other types of 
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cancer (201–203,205,210).  We now demonstrate that this process occurs in premalignant BE 
and EAC.  Although retrotransposition does not occur in all BE and EAC patients and recurrent 
insertions were not found, L1 may still participate in carcinogenesis.  It appears that although 
epithelial cancers are permissive for retrotransposition, there may be other factors mediating this 
process that allow it to occur in certain individuals more than in others.  Identifying the factors 
underlying the activation of retrotransposition, as well as the contributions it makes to 
carcinogenesis, will be essential to improve our understanding of genomic instability generated 






















LINE-1 Expression and Retrotransposition in Normal Esophagus and  













Squamous cell carcinoma of the esophagus (SCC) is the most common form of esophageal 
cancer in the world and is frequently diagnosed at an advanced stage when successful treatment 
is challenging.  Understanding the mutational profile of cancer is necessary to develop robust 
and successful treatments.  Because many groups, including our own, observed somatic 
retrotransposition in tumors of the digestive system, we focused on LINE-1 (L1) mobilization as 
a source of instability in this cancer.  We hypothesized that retrotransposition is ongoing in SCC 
patients.  The expression of L1 proteins is necessary for active retrotransposition to occur; 
therefore, we evaluated the expression of open reading frame 1 protein (ORF1p), a protein 
encoded by L1.  Using immunohistochemistry we detected ORF1p expression in all four of the 
nine available SCC cases. After L1-seq, we confirmed 74 somatic insertions in the tumors of 
eight of nine individuals evaluated.  Interestingly, we found 12 insertions that appeared to be 
sub-clonal in the adjacent normal esophagus while likely clonal in the tumor using both 
conventional and nested PCR.  Overall, our results indicate that L1 retrotransposition is active in 
squamous cell carcinoma of the esophagus and that early events occurring in histologically 









 Squamous cell carcinoma  of the esophagus (SCC) is the most common esophageal 
cancer in the world and its incidence differs across various geographic areas; its incidence is low 
in North America but it commonly occurs in parts of Eastern Asia (269,270).  SCC develops 
from the cells comprising the squamous esophageal mucosa and its main risk factors include 
combined alcohol and tobacco use, consumption of scalding beverages, and a diet low in fresh 
fruits and vegetables (269,271).  Esophageal squamous cell carcinoma is the major histologic 
type of esophageal cancer in East Asian countries and is an aggressive tumor (272).  The cancer 
is especially common in rural, mountainous areas with little access to resources and minimal 
dietary diversity such as Northern Iran, central China, parts of South-East Africa, and South 
America (271,273–275).  Unfortunately, by the time SCC is diagnosed, greater than half of the 
patients have inoperable tumors or obvious metastases (272).  Even if the tumor is removable, 
the prognosis for most patients is still very poor; therefore, better methods for early detection and 
treatment are necessary (276).      
Recently many groups, including our own, have evaluated a mutation generating 
mechanism known as retrotransposition and its role in epithelial cell cancer development (201–
206,208,210).  During retrotransposition, a sequence of DNA mobilizes via an RNA mediated 
“copy and paste” mechanism.  L1 elements are the only autonomous retrotransposons in the 
human genome.  These elements mobilize themselves by promoting their own transcription 
followed by the translation of the two open reading frames coding for proteins necessary for the 
element’s reintegration into the genome.  The movement of all other retro-elements in the human 
genome (Alu, SVA, and processed pseudogenes) is dependent on the activity of L1 elements.  
Because retrotransposons are potentially mutagenic when inserting into new sites in the genome, 
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host cells inhibit their activity by suppressing transcription and translation 
(60,61,63,74,75,78,79,85,277,278).  L1 expression levels are inversely correlated with 
methylation of the promoter in the 5’ UTR of the element and numerous epigenetic modifiers 
contribute to establishing and maintaining the methylation status of L1 elements in the genome 
(68,71,279,280).  A known feature of SCC is hypomethylation of L1 elements throughout the 
genome; furthermore, the less methylation present, the worse the prognosis for the patient (281).  
Additionally, we have observed L1 protein expression of ORF1, open reading frame 1, in normal 
squamous epithelium of the esophagus indicating the L1 is potentially active in the relevant 
normal tissue (206).   
We hypothesized that in some individuals, L1 is active in a subset of cells in the normal 
squamous epithelium and its subsequent insertions may contribute to the process of esophageal 
squamous cell tumor development.  When one or more of the host control mechanisms fails, L1 
is capable of mobilizing and increasing the mutational burden of the genome.  In cancer, 
genomic instability and hypomethylation may create a hospitable environment for L1 expression 
and mobilization.  Therefore, we expected that in SCC, a cancer known to be hypo-methylated at 
L1 promotors, L1 elements would express proteins more robustly and increase activity.  In a 
previous study, we demonstrated that a sub-clonal insertion occurred in the histologically normal 
tissue of the esophagus and was expanded in the subsequent metaplastic condition of a patient 
(206).  We also observed a sub-clonal insertion which occurred in histologically normal tissue, 
was maintained in the population of metaplastic cells, and then expanded in the subsequent 
esophageal adenocarcinoma (206).   
To test our hypothesis, we evaluated L1 mobilization in individuals with esophageal 
squamous cell carcinoma using L1-seq, a high-throughput L1 targeted next-generation 
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sequencing method (249).  We observed L1 activity in SCC and in NE and demonstrated that 
sub-clonal insertions occur in normal squamous epithelium at a higher rate than previously 
observed in other cancer types (204,206).  
 
Table 3.1: This table shows the overall number of validated somatic insertions in each group of 
patients.  It also contains the metrics for L1-seq, namely, the number of reference and non-
reference insertions detected with next-generation sequencing for each library which give an 












SCC patients Known reference
Known non-
reference
Reads required Map score
SCC/EAC 1 5 4 1005 350 10 0.3











SCC/EAC 1 5 4 4 17 0 0
SCC 2 5 5 4 48 12 0
L1-seq detected reference, non-reference, and somatic insertions in SCC patients
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Materials and Methods 
L1-seq. Using the DNeasy kit from Qiagen, we isolated DNA from thinly shaved 
sections of fresh-frozen tissue embedded in OTC freezing media.  Five pairs of our patient 
samples were micro-dissected with the assistance of pathologist Robert A. Anders (including 
samples: 20, 21, 22, 23, and 24 N and T).  The microdissection removed all normal tissue from 
the tumor, and all tumor tissue from the normal, in addition to removing areas where necrosis 
was evident.  Equal amounts of genomic DNA from each individual were pooled by group 
(either normal or tumor) in the same manner previously used (206).  L1-seq uses a hemi-specific 
PCR and eight degenerate primers to selectively amplify human-specific active L1 elements in 
the human genome (249).  Following the PCR phase of L1-seq, we excised products between 
200 and 500 nucleotides from a 1% agarose gel and purified them with the Qiagen gel 
purification kit.  We analyzed the libraries on the Bioanalyzer 2100 and then combined the 
products in equimolar ratios from the eight different degenerate primer reactions.  We sent the 
libraries for next-generation sequencing on the Illumina HiSeq 2500, aligned resulting reads with 
Bowtie2, and sorted the reads based on the presence or absence of L1 sequence.  We also 
segregated and excluded all previously published polymorphic L1 insertions and reference 
insertions from our list of putative somatic insertions using the L1-seq pipeline established by 
Adam Ewing (249).  Overall, our bioinformatics analysis was identical to previous studies 
(206,249).   
Stringency analysis. 
We filtered the putative somatic insertions detected by L1-seq using a map score of 0.5 or 
greater, a nucleotide window of 90 base pairs or greater, and 3 or more unique reads.  After 
filtering with the aforementioned criteria, we then attempted our PCR validations with both 
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conventional and nested PCR in all samples.  There parameters gave relatively good validation 
rates of 50% and ~69% for the two groups of SCC samples respectively and are comparable to 
validation rates in previous publications (203,204,206).   
Immunohistochemistry. 
We performed our immunohistochemistry (IHC) experiments using the EnVision 
System-HRP (catalog K4006; Dako) according the manufacturer’s protocol.  We performed the 
primary antibody incubation with a mouse monoclonal ORF1 (1.25 mg/mL) at a 1:3,000 dilution 
for 40 minutes at room temperature.  We performed secondary antibody incubation as per the 
manufacturer’s protocol.  The monoclonal antibody used detects amino acids 35-44 of the ORF1 














L1 Protein Expression in NE and SCC in the Esophagus 
In order to establish L1 activity in patients with SCC and the normal esophagus of SCC 
patients, we evaluated L1 protein expression in both normal and tumor samples.  Although 
LINE-1 protein expression is necessary for LINE1 mobilization (282), it is not sufficient to 
ensure somatic insertions will occur, even in cancer (Doucet-O’Hare et al., 2015).  Rodić and 
colleagues suggested that ORF1p expression is a potential biomarker in cancer due to its 
pervasive expression in many types of epithelial cancer (209).  Even in the absence of confirmed 
somatic insertions, we previously observed ORF1p expression in all esophageal adenocarcinoma 
samples evaluated(206).  Furthermore, we observed weaker ORF1p expression in the normal 
squamous epithelial tissues of many patients coinciding with a few insertions that likely occurred 
in the normal tissue originally and expanded in the resulting lesion (145). 
Due to the expression of ORF1p in many epithelial cancers (208), we hypothesized there 
would be ORF1p expression present in SCC.  Additionally, we expected to observe weaker 
ORF1p expression in the normal squamous epithelium of the patients (145).  We obtained 
formalin-fixed paraffin-embedded tissue samples for four of the nine patients, and using a 
monoclonal OFF1p antibody (256) confirmed ORF1p expression in all samples evaluated.  Three 
of the four cases evaluated with IHC showed robust ORF1p staining; however, in one case it was 
much weaker (Fig. 3.1).  Intriguingly, the SCC case in which ORF1p expression was low was the 
only case in which no somatic insertions were confirmed (Table 3.2).  We also observed low-
level ORF1p expression in normal squamous epithelium of all patients evaluated (Fig. 3.1).   
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ORF1p expression in epithelial cancer typically appears in a diffuse to speckled 
distribution in the cytoplasm of the cancer cells.  Although ORF1p was present in all four 
samples evaluated, the distribution pattern differed among samples and across regions of the 
same sample.  In some samples, we observed ORF1p expression predominantly in a diffuse 
pattern in the cytoplasm of the cells, while in three samples, we observed an accentuated 
perinuclear pattern oftentimes with aggregates of the protein localizing near the nuclear 
periphery (Fig. 3.2).  We confirmed the perinuclear staining pattern with a second antibody 
targeting a different portion of the ORF1 protein (206); however, the significance of these 















Figure 3.1: ORF1p expression in normal esophagus and squamous cell carcinoma A) and 
B) Representative photomicrographs depicting LINE-1 ORF1p expression in normal esophageal 
squamous epithelium (black arrows) and in esophageal squamous cell carcinoma cases (red 
arrows): A) and B) Esophageal tissue with normal squamous epithelium adjacent to squamous 
cell carcinoma from two separate individuals stained with LINE1 ORF1p (final magnification 
x100). 
 
Figure 3.2: ORF1p expression patterns in esophageal squamous cell carcinoma 
A) and B) photomicrographs showing an invasive squamous cell carcinoma case where peri-
nuclear staining patterns manifest for ORF1p. A) Final magnification x100. B) The same case as 
A) with a higher magnification view of ORF1p peri-nuclear staining accentuation (within red 













































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 3.2: This table lists all confirmed somatic insertions, the sample in which the insertion 
occurred in addition to all pertinent characteristic of the insertion such as endonuclease cleavage 
site, poly (A) tail length, genomic breakpoint, the gene into which the insertion occurred, the 


















Somatic L1 Insertions in Squamous Cell Carcinoma of the Esophagus 
After observing ORF1p expression in all SCC cases evaluated, we characterized the 
potential mutations caused by L1 activity in esophageal squamous cell carcinoma by studying 
the same patients’ matched fresh-frozen normal and cancer tissues.  Because SCC is a relatively 
rare cancer in the United States, we were only able to acquire nine samples total for our study 
(283).  We received the samples in two groups, the first group consisted of four individuals with 
SCC and one individual with esophageal adenocarcinoma (EAC), and the second group 
consisted of five individuals with SCC (Table 3.1).  We prepared DNA from each of the two 
groups into L1-seq libraries separately and the samples were next-generation sequenced and 
analyzed.  L1 seq is a high throughput technique which enriches for the human-specific sub-
family of L1 elements using specific PCR primers.(249).  After sequencing, the data were 
subjected to a computational pipeline, designed by Ewing and colleagues, that analyzes 
sequencing data and identifies potential somatic insertions present in tissue  
Evidence of active L1 elements manifests in the form of both protein expression and 
“somatic” insertions.  As in our previous studies, we defined somatic insertions as those which 
were not inherited from a previous generation and therefore present in only a subset of cells 
within a tissue (206).  Although the majority of somatic insertions are expected to occur in the 
tumor and to be absent from the normal tissue, we hypothesized that some somatic insertions 
may exist in a sub-clonal population of normal esophageal cells.  The sub-clonal insertions could 
be amplified when cells are selectively amplified during tumor initiation and progression (206).  
Due to the previously observed sub-clonal insertions in normal esophagus and Barrett’s 
esophagus (206), we evaluated every putative insertion with both conventional PCR and nested 
PCR in both normal and tumor DNA (Fig. 3.3 and 3.4). 
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In order to select putative insertions for validation with PCR and Sanger sequencing, we 
filtered our results by selecting insertions with 3 unique reads or more, greater than a 90 base-
pair nucleotide window, and a map score of 0.5 or greater (249).  After filtering in the first group 
of samples, we observed 100 potential tumor only insertions and tested 36 of them.  Using PCR 
and Sanger sequencing we were able to validate 18 insertions distributed among the four 
individuals with SCC.  We did not validate any somatic insertions in the individual with EAC; 
however, we previously validated somatic insertions in other patients with EAC (206).  
After filtering the data for the second group of samples, there were 133 potential 
insertions unique to the tumor, 82 of which were tested.  We validated 56 insertions distributed 
among four of the five individuals with 12 of the insertions appearing to be sub-clonal in the 
normal esophagus and clonal in the tumor (Fig. 3.3).  Interestingly, all four patients with 
confirmed somatic insertions in the second group of samples harbored sub-clonal insertions in 
the normal tissue.  We previously detected somatic insertions in normal tissue with nested PCR 
for approximately 5% of somatic insertions (204,206).  In esophageal squamous cell carcinoma 
samples, we observed that ~16% (12/74 insertions) were present in the normal esophagus with 
nested PCR (Figures 3.3 and 3.4).  We speculate that the sub-clonal insertions in the normal 
esophagus could have occurred in a single cell which then transdifferentiated into dysplasia and 
then squamous cell carcinoma.  In the process of tumorigenesis, the cells with the insertions may 
have been selectively amplified and thus the insertions in the tumor cells were easily detectable 
with a conventional PCR (206,264).  Furthermore, the incidence of sub-clonal insertions in the 
normal tissue does not appear to be a rare phenomenon in SCC as it is present in four out of the 
eight patients with confirmed somatic insertions (Table 3.2).   The sub-clonal insertions observed 
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in the normal tissue are unlikely to be a result of contamination from the tumor DNA because 
each of these samples was micro-dissected under the guidance of a gastrointestinal pathologist.   
Unfortunately, only normal esophagus and tumor were available from the patients; 
therefore, we cannot be certain that the confirmed somatic insertions observed in both tissues 
were not low-level germline insertions.  The sensitivity of the conventional PCR method for 
somatic insertion confirmation is approximately one in ten, e.g. if one in ten cells has the 
insertion present it is consistently detected at a low level by conventional PCR(204).  Using 
nested PCR, we consistently detect an insertion present in one out of a thousand cells (204).  
Although it is unlikely for a sub-clonal insertion to be germline, we cannot determine that the 
sub-clonal insertions detected in normal tissue are definitive somatic insertions.  To date, there 
are no known germline insertions present at such a low frequency in an individual’s tissue.  
Tumor-specific insertions detected are also unlikely to be germline because they were absent 
from normal esophageal tissue with nested PCR (Fig 3.5).    
Characterization of Tumor Specific Insertions 
After establishing that L1 was actively mobile in eight of the nine cases of SCC 
evaluated, we evaluated more thoroughly the characteristics of the confirmed somatic insertions.  
To identify the precise base pair at which the insertions occurred we performed PCRs to amplify 
the 5’ end of the insertions and were able to successfully amplify and sequence 23/74 (Table 
3.2).  For a subset of confirmed insertions, we identified endonuclease cleavage sites and target 
site duplications (TSDs) which are both hallmarks of the process of retrotransposition (Table 
3.2). Out of the 20 putative endonuclease cleavage sites identified in our study,  9 were similar 
(differed by 3 base pairs or less) to the canonical endonuclease cleavage site in target-primed 
reverse transcription reactions (111).  With regard to 4 insertions presumed to be endonuclease 
95  
 
independent (284), all had deletions at the site of insertion integration (265).  For some of the 
confirmed insertions, we identified the TSDs ranging from two base pairs in length to 389 base 
pairs in our samples.  The insertion sizes varied from 120 to 1,859 base pairs with 11 of the 
insertions under 500 base pairs (Table 3.2).  In a previous study, we observed similar results with 
regard to insertion size, endonuclease cleavage sites, and insertion sizes (206).  Furthermore, five 
of the insertions had 5’ end inversions, a finding consistent with previous studies of germ-line 
insertions and L1 insertions in cancer (111,201–203,205,206,210).  Of the insertions validated in 
SCC patients, 40 amplified easily with a single PCR, while the remaining 34 insertions amplified 
only following a nested PCR (Fig. 3.3).  We confirmed 12 insertions in normal tissue with only a 
nested PCR, but those insertions amplified with a conventional PCR in the tumor DNA (Fig 3.4).       
At least half of the somatic insertions validated in the SCC patients had characteristics 
that differ from a canonical germline insertion (51,111).  We confirmed that 4/23 insertions had 
deletions (17.4%) at the site of integration; however, only 10% of germline insertions normally 
have integration-site deletions (111).  The four insertions with integration site deletions also 
lacked clear target-site duplications, both of which are clear hallmarks for canonical 
retrotransposition, suggesting they were endonuclease independent (254). Furthermore, a little 
less than half of all validated somatic insertions were 500 base pairs or less due to severe 5’ 
truncation.  In contrast to others’ work, we did not detect any 3’ transductions (202); however, 
L1-seq rarely detects such events.   
None of the somatic insertions evaluated occurred in exons; however, 32 insertions did 
occur into the introns of 32 different genes.  One of the insertions occurred into an intron of two 
different genes, namely C8orf37-AS1 and LOC100616530. Another gene, KCNIP4, had two 
different confirmed insertions in an intron approximately 280 kb apart (Fig 3.6).  Although 
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KCNIP4 is approximately 1.2 Mb in size, the insertions occurred in two different individuals, 
meaning that this gene was recurrently subjected to L1 insertions. The insertions in KCNIP4 are 
in opposite orientations relative to the gene.  Of the 32 genes with validated somatic insertions, 
22 occurred into genes that have previously been associated with cancer (Table 3.3).  Our 
findings reveal a statistically significant enrichment of validated somatic insertions into genes 
previously associated with cancer (P < 1 x 10-10) (284-327).  We considered the probability that a 
somatic insertion would hit more of the cancer-associated genes than would be expected due to 
chance alone.  After accounting for gene size, we observed a significant enrichment of somatic 
insertions into cancer associated genes using a chi squared test (P < 1 x 10-10).  Four of the 22 
genes are considered “known cancer genes” by the network of cancer genes (285), and the 
remaining 18 genes are candidate cancer genes which have been associated with cancer in the 
literature (Table 3.3)(286–328). Interestingly, out of the 22 genes associated with cancer, 
sequence variation in 16 of the genes have also been associated with smoking (Table 3.3)(329–
336).  Smoking is one of the main risk factors for SCC; therefore, it is fitting that so many of the 



















































































































































































































































































































































































































































































































































































































































































































































































Table 3.3: The gene listed in this table all had validated somatic L1 insertions into introns.  All 
of these genes have been associated with cancer and many of them have also been associated 




















Expanding our understanding of carcinogenic mutational mechanisms will lead to earlier 
diagnosis and better treatment opportunities for cancer patients.  Although esophageal squamous 
cell carcinoma is rare in the United States, its prevalence throughout the rest of the world, 
necessitates its study.  In order to detect, diagnose, and treat SCC effectively, we need a thorough 
evaluation of mutations acquired in the squamous tissue of the esophagus, both in the normal 
tissue and in dysplastic tissue, which transitions to cancer. Cellular processes often become 
dysregulated during carcinogenesis and may provide a favorable environment for the activity of 
retrotransposons.   
Before evaluating cancer samples for newly acquired somatic insertions, we looked for 
L1 protein expression differences between the normal squamous epithelium and the tumor.  We 
observed higher ORF1p expression in the SCC patients possessing a larger number of confirmed 
somatic insertions.  Because we were only able to acquire tissue for four of the nine SCC patients 
studied, our results are not statistically significant.  Previously, we hypothesized that higher 
ORF1p expression correlates with a higher number of somatic insertion occurrences in patients; 
nevertheless, this did not hold true for our EAC and Barrett’s esophagus patients.  Interestingly, 
in the present study multiple patterns of ORF1p staining appeared in the cancer of three 
individuals including a diffuse cytoplasmic pattern and a perinuclear pattern with accentuation 
and protein aggregates near the nuclear periphery (Fig. 3.2).  While we do not fully understand 
the significance of these ORF1 protein expression patterns in SCC, we can conclude that the 
protein is present in all samples evaluated, and that there are differences in level and pattern of 
expression between patient samples. 
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 Our group and many others have firmly established that L1 somatic insertions occur 
frequently in epithelial cancers and presented evidence that insertions may sometimes contribute 
to cancer development (201–206,210,237).  In this study, we demonstrate retrotransposition is an 
active process in eight out of nine patients with SCC.  We observed 62 somatic insertions absent 
from normal tissue and present in the tumor and 12 insertions that amplified easily with a 
conventional PCR in tumor, but were also present in the matched normal tissue using nested 
PCR (Fig. 3.3, 3.4). There was no significant correlation between age and insertion occurrence 
(Fig. 3.7).  
 Faulkner and colleagues first detected somatic insertions into normal hippocampus and a 
few years later, we detected a somatic insertion in normal colon and two somatic insertions in 
normal esophagus (204,206,220).  Aside from the aforementioned examples, observations of 
somatic insertions in normal tissues are relatively uncommon (221).  Interestingly, we detected 
twelve instances of somatic insertions in normal tissue with nested PCR suggesting the insertions 
are in only a few cells.  With conventional PCR, the same insertions are observable in tumor 
DNA exemplifying that a larger number of cells contain the insertions in the tumor.  Because the 
frequency of sub-clonal insertions in normal esophagus of SCC patients is much higher than we 
have previously observed in cancer patients, it appears that the esophagus is permissive for L1 
somatic insertions (204,206).  Our data are consistent with two different models explaining the 
role of retrotransposition in cancer.  First, it is possible, as previously suggested(204,206,264), 
that some somatic L1 insertions are acquired in the normal tissue and subsequently expand in the 
cancer (Fig. 3.5).  In future studies, single-cell sequencing should reveal the occurrence of 
somatic L1 insertions in normal cells and give insight with regard to their frequency.   
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Many groups detected somatic retrotransposition events in various types of epithelial 
cancer such as squamous cell lung, head and neck, hepatocellular, breast, prostate, colorectal, 
bone, esophageal adenocarcinoma, pancreatic ductal carcinoma, and endometrial cancer (202–
206,208,210,337).  We confirmed somatic retrotransposition is active in esophageal squamous 
cell carcinoma in eight of nine patients evaluated; furthermore, we observed twelve instances 
where retrotransposons actively mobilized in normal squamous epithelium of the esophagus.  
Understanding the role of somatic insertions in cancer relies heavily on having an accurate 
estimation of retrotransposon activity in normal cells.  In light of these data, we must establish 
the underlying rate of retrotransposition in any normal tissue subsequently evaluated in a disease 













Figure 3.3: Examples of sub-clonal insertions in normal esophagus Conventional PCRs done 
on normal esophagus and esophageal squamous cell carcinoma alongside the corresponding 
nested PCRs. The nested PCRs use the product from the conventional PCRs and a new pair of 
primers, which are nearer to the predicted breakpoint of the somatic insertion.  These PCRs 
showcase events which presumably occur in the normal esophageal tissue and are expanded 











Figure 3.4: L1 structure and L1-seq validation scheme A) LINE-1 structure of a human 
specific active element in the human genome.  Full-length L1 elements are approximately 6,000 
nucleotides in length and have a 5’ untranslated region, containing both a promoter and an anti-
sense promoter.  L1 encodes two open reading frames for proteins on which it relies for its 
mobilization in the cell (21).  The first open reading frame encodes ORF1p, a protein with RNA 
chaperoning activity that includes a coiled-coil domain (CCD), an RNA recognition motif 
(RRM), and a carboxy-terminal domain (CTD) (24,29).  The second open reading encodes 
ORF2p, possesses an endonuclease domain (EN) and a reverse transcriptase domain (RT) 
(25,36,38).  The element also has a poly(A) tail between the 3’ untranslated region and the target 
site duplication (TSD).  Both the poly(A) tail and TSDs are hallmarks of the target-primed 
reverse transcription, the process by which L1 elements mobilize (49). B) The PCR validation 
method for predicted somatic insertions utilizes two unique areas of sequence in the 3’ end of the 
L1 element.  The sequence ‘ACA’ is incorporated into the L1 ACA primer and is positioned 
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about 90 nucleotides from the poly(A) tail.  The ‘ACA’ nucleotides (94,95) distinguish the 
human specific transcriptionally active L1 element from other L1s in the genome and allow for a 
specific PCR product to amplify.  The L1 G primer has a ‘G’ nucleotide which is also unique to 
the human specific active L1 element and the nucleotide is approximately ten nucleotides 
proceeding the poly(A) tail (249).  In order to validate an insertion, pictured adjacent to a poly-A 
tail, the L1 primers are used in conjunction with filled and empty site primers to amplify the 3’ 
end of the somatic insertion.  The nested empty site and nested filled site primers are flanked by 
the empty and filled site primers and are used to verify that insertions predicted in tumor are 
truly absent from normal tissue.  Additionally, nested primers are utilized when amplifying low 
copy number somatic insertions because they are able to detect when one cell out of a thousand 
has a copy of an insertion.  The size of the expected products and relative locations of the 












Figure 3.5: Acquisition, Detection, and Validation of sub-clonal and clonal somatic 
insertions in L1-seq This diagram details the sensitivity of L1-seq with regard to detecting 
somatic insertions at differing levels of clonality in a tissue and different scenarios by which a 
somatic insertion could become amplified in a tumor.  (A) An insertion at a very low frequency 
(less than one in a thousand cells) in the normal esophagus and at an undetectable level in the 
tumor when evaluated by L1-seq.  (B) An insertion at an undetectable level in the normal 
esophagus and a sub-clonal but detectable level in the tumor.  (C) An insertion at an  
undetectable level for L1-seq in the normal esophagus which subsequently becomes clonal in the 
tumor. The insertion is not detectable with conventional PCR in the normal, but can be detected 
with a nested PCR.  (D) An insertion which is clonal in both the normal esophagus and the 





Figure 3.6: Somatic insertions occurrence, ORF1p expression, and patient age.  This figure 
details the ages of the patients compared with the number of somatic insertions which occurred 
in each individual and the level of ORF1p expression observed in the individual.  The graph 
shows there is a small positive correlation between the age of the patients and the insertion 
occurrence into them, e.g. older patients tend to have more somatic insertions.  However, the 
positive correlation between age and insertion occurrence is not statistically significant when a 










Figure 3.7: Somatic insertions occurrence, ORF1p expression, and patient age.   
This figure details the ages of the patients compared with the number of somatic insertions which 
occurred in each individual and the level of ORF1p expression observed in the individual.  The 
graph shows there is a small positive correlation between the age of the patients and the insertion 
occurrence into them, e.g. older patients tend to have more somatic insertions.  However, the 
positive correlation between age and insertion occurrence is not statistically significant when a 






























Retrotransposition: Cause or Consequence? 
 Even after all the work done to characterize mobile DNA activity in various tissues and 
diseases we are still unable to definitively state that retrotransposons are more than a rare cause 
of disease.  Although there are more than one hundred examples of disease due to 
retrotransposons, it is certainly more of an exception than a rule.  Many, including myself, have 
argued that due to the dysregulation of many cellular processes during carcinogenesis and 
thereafter, retrotransposons may simply be less restricted and therefore successfully mobilize at a 
higher rate than in normal tissues.   Evidence of active retrotransposition has been observed in 
many cancers (202–206,210,244,337) and is notably frequent in epithelial cancers.   
Although many groups have reported evidence of somatic insertions in cancer, very few 
have shown evidence that a somatic insertion contributed to the development of cancer.  A 
somatic insertion into the APC gene of a patient with colorectal cancer was the first observed 
example of a L1 insertion contributing to carcinogenesis in 1992 (237).  Many years later, 
another definitive somatic insertion was found in an exon of the PTEN tumor suppressor gene 
(210).  Finally, a tumor-specific, presumably somatic, insertion into the gene ST18 was observed 
in a patient with hepatocellular carcinoma (205).  The insertion activated the suppression of 
tumorigenecity 18 gene, ST18, and interrupted a negative feedback loop blocking ST18 
repression of its enhancer (205).  Other than the aforementioned examples, no other strong 
evidence has been published to suggest that retrotransposons, L1 in particular, have contributed 
to carcinogenesis in individuals through somatic insertions.  Somatic insertions may not be the 
only way in which retrotransposons contribute to carcinogenesis, as suggested by Shukla and 
colleagues in a study on hepatocellular carcinoma (205).  In 4/19 patients evaluated, germline 
insertions into the tumor suppressor MCC, mutated in colon cancers, and subsequent absence of 
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MCC expression was confirmed (205).  Clearly, it is possible for retrotransposons to contribute 
to cancer development; however, the question remains- how often does it occur? 
When studying a specific disease such as esophageal carcinoma, we must work 
backwards starting with the cancerous tissue sample and attempt to reconstruct the process which 
lead to its existence; however, this is far from an ideal way to determine if retrotransposition 
contributes to cancer development.  Even when insertions are detected in key genes, extensive 
functional studies need to be performed to show that the gene itself is being aberrantly expressed.  
Even if the gene is not being expressed as it should be, it is often still unclear how it’s 
overexpression or under-expression lead to the disease developing.  In fact, many of the cancer 
genes listed in databases such as the ‘Network of Cancer Genes’ are only cancer-associated 
genes since they have not been definitely shown to contribute to tumorigenesis (285).  
It would be ideal to model what occurs following the disruption of cellular 
retrotransposition control and whether or not the increased activity results in cancer.  A study, 
like the aforementioned one, could be done in an animal model, although modeling the 
dysregulation of the many pathways which modulate retrotransposition would be arduous and 
potentially cost prohibitive.  It would be necessary to not only model the dysregulation of each 
pathway controlling retrotransposition individually, but also to model them in various 
combinations.  Due to the complex nature of modeling the many pathways contributing to the 
tight retrotransposon regulation, it would be much easier to accomplish such a study in cell 
culture.  After finding captivating evidence in a cell culture model that one or more pathways in 
concert promote retrotransposons to participate in carcinogenesis, the experiment could then be 
repeated in an animal model for confirmation.  Essentially, a great deal of work remains to be 
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accomplished in order to plainly show that retrotransposons participate in cancer development on 
a semi-regular or regular basis.    
Understanding individual variation and evaluating retrotransposon activity in 
histologically normal tissue 
 Recent findings from our lab and others have confirmed that insertions occur in normal 
GI tissues such as liver, colon, and esophagus occur and in some cases are then amplified in a 
tumor of the same tissue (204–206).  The key to understanding retrotransposon’s contribution to 
carcinogenesis may be in understanding the frequency at which elements mobilize in normal 
tissue and are subsequently selected for amplification.  To acquire a better estimate of 
retrotransposon activity in histologically normal tissue, a significantly larger number of 
individuals need to be evaluated.  Missing sub-clonal somatic insertions present in normal tissue 
could also be due to the methods used to validate predicted insertions.  For example, in our work, 
we check every validated somatic insertion with a nested PCR in both the tumor and in the 
normal.  We have shown that our nested PCR amplifies as little as one insertion in a thousand 
cells (204).  Unfortunately, only our lab has utilized nested PCR to robustly determine whether 
or not insertions validated in tumor samples are truly absent from the matched normal tissue 
even at a low concentration (204,206).   
To date, 598 cancer and/or precancerous condition patients’ genomes have been 
evaluated for retrotransposon activity; however, in only 38 of these cases nested PCR was 
utilized to ensure somatic insertions detected were truly absent from the normal tissue (201–
206,210,244).  For about 10% of the patients evaluated, 61 of 598, blood was utilized for the 
matched normal control in the study.  Using blood as the normal tissue in a study of 
retrotransposition is far from ideal because sub-clonal insertions in the matched normal tissue 
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will be missed entirely.  Even using nested PCR, we are limited in the sensitivity we have to 
detect sub-clonal insertions as we cannot detect insertions which are at a lower concentration 
than 1/1000 in a sample (204).   
Knowing the rate of sub-clonal insertions in the normal tissue will allow us to determine 
the likelihood that an insertion will occur into a gene whose up-regulation or down-regulation 
might confer a selective advantage upon a cell and lead to carcinogenesis.    Single cell 
sequencing would be an ideal way to increase our sensitivity to detect insertions which are rare 
in the normal tissue.  Because single cell sequencing may be cost prohibitive for looking at 
thousands of cells from each individuals studied, nested PCR could initially be used to screen 
individuals who have sub-clonal insertions which are detectable at 1 in 1000 cells.  After 
individuals who are known to have sub-clonal insertions in normal tissues have been identified, 
their samples could be single cell sequenced to determine the frequency with which the sub-
clonal insertions occurred in their normal tissue.   
It has been evident from the many studies performed to date that retrotransposition is 
active to different degrees in different individuals.  Among individuals with somatic insertions in 
their tumors, there are ‘jackpot’ winners who likely have hundred or even thousands of somatic 
insertions and there are individuals who do not possess a single detectable somatic insertion.  
The variation among individuals with regard to the activity of their mobile DNA is largely a 
mystery even though many pathways which restrict these elements are known.  It has been 
shown that methylation of L1 promotors is inversely correlated with their expression in cancer 
patients in vivo; however, L1 expression does not necessarily mean that retrotransposition is 
occurring.  In order to characterize what factors play a role in the successful retrotransposition of 
elements in cancer genomes, more individuals must be evaluated.  When an individual has many 
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validated somatic insertions, he or she should undergo an expression profile including all 
pertinent genes involved in mobile DNA suppression in humans.  Only by evaluating a larger 
number of individuals and aggregating the data can we hope to achieve an understanding of why 
some individuals have very active retrotransposons in their tumors and others do not.   
Concluding Remarks 
 As reviewed in chapter 1, there is considerable prior evidence that L1 is not only a source 
of inter-individual genomic variation, but also active in the cancer genomes of many patients.  
The results presented in chapters 2 and 3 of this thesis serve as further evidence that L1 is active 
in cancer; furthermore, this work shows that L1 is also frequently active in normal tissues and 
precursor diseases to cancer as well.  Although our work has contributed to the overall 
knowledge of L1 activity in disease, it is still uncertain to what extent it is contributing to 
carcinogenesis in general.  In summary, these results reinforce the fact that the human genome is 
still susceptible to somatic insertions and the rate of acquisition of said insertions varies greatly 
between individuals.  It will be key in the future to secure our understanding of the role of 
retrotransposition in all disease, not just in cancer, only then can we full appreciate its full effect 




























Updated L1-seq protocol 
Summary 
L1-seq is a high-throughput sequencing technique which is utilized to identify novel L1 
insertions in genomic DNA samples of interest. Using special diagnostic nucleotides unique to 
the youngest and most active L1 sequence, we can amplify new somatic insertions. This 
technique has helped to establish the number of L1 insertions present in the general population as 
well as the variation among individuals with regard to their complement of active L1 elements. 
More recently, this technique has been employed to assess the level of retrotransposition 
occurring in various diseases such as cancer. These efforts try to establish a connection between 
the process of retrotransposition and disease development and/or progression. 
Introduction 
Retrotransposons are nearly ubiquitous in eukaryotes from slime molds (338) to humans (111) 
and have contributed greatly to genome composition of these organisms. Retrotransposons make 
up 45% of the human genome(111). In particular, the LINE-1 (L1) element, has contributed to 
approximately 17% of the human genome and continues to add to it via a copy and paste 
mechanism with an RNA intermediate(111). L1 is the only autonomous retrotransposon in the 
human genome because it encodes two proteins necessary for mobilization and reinsertion into 
the genome; however, these two proteins, once expressed can mobilize other types of 
retrotransposons as well as processed psuedogenes(31,48,51). Each individual has a different 
complement of potentially active L1 elements; although, the majority of the L1s in each 
individual’s genome are truncated and therefore inactive. L1-seq(249) was developed to help 
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characterize L1 variation among individuals because L1s have contributed to a substantial 
fraction of the genome and are capable of inducing many types of mutations. L1-seq has since 
been used to evaluate several types of cancer to establish the level of retrotransposition occurring 
in colon cancer, lung cancer, breast cancer, and many other cancers(201,203). Additional 
sequencing techniques have confirmed the L1-seq data and demonstrated that L1 elements are 
active in many cancer types(201,202,205,206,210,220,221). The results have demonstrated that 
L1s are active in a subset of patients with cancer, in addition, L1 elements are active in all 
epithelial cancers tested. The L1-seq technique consists of a DNA library prep as well as the 
validation of the predicted new insertions detected in the samples used. Although few of the 
insertions may be directly responsible for the development of the disease, it should be possible to 
utilize known insertions present in a cancer sample for monitoring the cancer’s progression to 
metastasis. To detect metastasis using a new L1 insertion, a PCR would be performed on serum 
DNA from a patient to determine whether or not the insertion was detectable in the blood and 
therefore potentially in a floating cancer cell. This technique is useful for both evaluating the 
overall complement of L1 elements in a genome as well as looking for new insertion events. L1-
seq utilizes unique nucleotides, ‘ACA’ 91-93 nucleotides from the 3’ end of the element, to 
selectively amplify the young and active subset of elements in the human genome (6). Following 
the initial 5 cycles of the PCR, wherein the linear amplification of L1 elements occurs, 
degenerate primers are added to the mixture to exponentially amplify both polymorphic and 






Store all reagents as specified by manufacturers. Diligently follow all waste disposal regulations 
when disposing of waste materials. All primers need to be diluted to 100 ɥM upon receipt in 
Diethylpurocarbonate (DEPC) water. Primers will be further diluted as specified later in the 
protocol. 
DNA Isolation 
1. DNeasy Blood and Tissue Kit (Qiagen) 
2. 500 mL of absolute ethanol (200 proof) 
3. QubitTM dsDNA BR Assay kit (Life Technologies) 
Library Preparation 
1. Promega GoTaq Flexi 
2. 25 mM MgCl2 
3. 10 mM dNTPs 
4. Diethylpurocarbonate (DEPC) water 
5. 100% DMSO 
6. Pfu polymerase 
7. 1 ɥg of good quality DNA per sample at a concentration of 100 ng/ɥL (notes). 
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8. LE agarose 
9. 1X TAE; Prepare 50X solution by dissolving 242 g Tris base in 750 mL of deionized water. 
Carefully add 57.1 mL glacial acetic acid, and 100 mL of 0.5 M EDTA (pH 8.0) and adjust 
solution to final volume of 1L. Dilute the 50X solution to 1x in deionized water. 
10. Ethidium bromide (10 mg/mL) 
11. QIAquick Gel Extraction Kit (Qiagen) 
12. MinElute PCR Purification Kit (Qiagen) 
13. Isopropanol (200 proof) 
14. 500 mL of Ethanol (200 proof) 
15. Agilent DNA 1000 kit or high sensitivity DNA kit (choose as needed, see notes). 
16. L1-seq primers (order HPLC grade for library preparation) 
Next-Generation Sequencing Data Analysis 
1. Server with at least 4GB of RAM and L1-seq scripts properly formatted 
(https://github.com/adamewing/l1seq) 2. Bowtie2 (http://bowtie-





1. GoTaq Green Master Mix (2X) 
2. Diethylpurocarbonate DEPC water 
3. DNA at concentration of 12.5 ng/ ɥL 
4. LE agarose 
5. 1X TAE; Prepare 50X solution by dissolving 242 g Tris base in 750 mL of deionized water. 
Carefully add 57.1 mL glacial acetic acid, and 100 mL of 0.5 M EDTA (pH 8.0) and adjust 
solution to final volume of 1L. Dilute the 50X solution to 1x in deionized water. 
6. Ethidium bromide (10mg/mL) 
7. QIAquick Gel Extraction Kit (Qiagen) 
8. Isopropanol (200 proof) 
9. 500 mL of Ethanol (200 proof) 
10. L1SP1A2 primer, L1nt112out, L1 “G” primer (see above) 
Methods 
Embedding and Cryosectioning Tissue 
1. To begin, embed each piece of tissue to be assayed in OCT freezing medium. You can simply 
put a thin layer of the media onto a pre-chilled (< 200 C) chuck. 
2. Quickly placing the thawed tissue section onto the OCT 
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3. Immediately cover the tissue in more OCT until it is barely visible through the medium. The 
OCT medium will change from clear to white, when the entire block of tissue/OCT is completely 
frozen, you can begin to cryosection the tissue for DNA extraction. It is best for the freezing to 
occur as rapidly as possible, to this end, a heat extractor can be used to enhance and shorten the 
freezing process and adherence to the chuck on which the tissue is being embedded in the OCT 
freezing medium. 
4. Set the cryostat to slice sections of tissue between 10 ɥm and 30 ɥm. 
5. During sectioning, carefully remove each roll of tissue and place 10- 20 slices into a pre-
chilled (< 200 C) 1.5 mL microtube. 
If the tissue sample is large enough, more than one tube of tissue slices can be made. Following 
the sectioning, tissue slices should be stored at -800C until it is time to isolate DNA. Embedding 
tissue in OCT freezing medium is only one way of extracting DNA from frozen tissue (notes). 
Extracting DNA from sectioned tissue 
1. Remove microtubes with tissue slices from -800 freezer and place them on ice. 
2. Add 360 ɥL of Buffer ATL (DNeasy Blood and Tissue kit). There is no need to further 
homogenize the tissue. Add 40 ɥL of proteinase K and mix thoroughly by vortexing (notes). 
3. Incubate at 550C overnight until the tissue is completely lysed. Vortex occasionally during 
incubation to help disperse samples. 
4. Vortex for 15 seconds. 
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5. Add 400 ɥL of buffer AL (DNeasy Blood and Tissue Kit) to the sample and mix thoroughly 
by vortexing. 
6. Immediately add 400 ɥL of ethanol (200 proof) and mix again thoroughly by vortexing 
(notes). 
7. Pipette 750 ɥL of the mixture (including any precipitate) into the DNeasy Mini spin column 
placed in a 2 mL collection tube (provided in the kit). 
8. Centrifuge at > 6,000 x g (8,000 rpm) for 1 minute. Discard flow through. 
9. Repeat steps 7 and 8 until all of mixture has been run though the same column for each 
sample. 
10. After the final spin with the aforementioned mixture, discard the collection tube and replace 
it with a new 2 mL collection tube. 
11. Add 500 ɥL of Buffer AW1. (Ensure that ethanol has been added to Buffer AW1 before use.) 
12. Centrifuge for 1 min at > 6,000 x g (8,000 rpm). 
13. Discard flow-through and collection tube and place the spin column in a new 2 mL collection 
tube. 
14. Add 500 ɥL of Buffer AW2. (Ensure ethanol has been added to Buffer AW2 before use.) 
15. Centrifuge for 3 minutes at 20,000 x g (14,000 rpm) to dry the DNeasy membrane and then 
discard flow-through and collection tube. 
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16. Place the DNeasy Mini spin column in a clean 1.5 mL micro-centrifuge tube and pipet 100 
ɥL of pre-warmed (550C) Buffer AE onto the DNeasy membrane. 
17. Incubate at room temperature for 10 minutes. 
18. Centrifuge for 1 minute at > 6,000 x g (8,000 rpm) to elute. 
19. Pipette an additional 50 ɥL of pre-warmed AE buffer directly onto DNeasy membrane. 
(There is no need to replace the micro-centrifuge tube. The additional DNA elution can be 
collected into the same tube up to a volume of no more than 150 ɥL.) 
20. Incubate for 10 minutes at room temperature. 
21. Centrifuge for 1 minute at 20,000 x g (14,000 rpm). 
This protocol is adapted from the Qiagen handbook for the DNeasy Blood and Tissue Kit 
(Catalog # 69504). 
Measuring DNA concentration (QubitTM) 
Use the QubitTM fluorometer to measure DNA concentration because it is one of the most 
accurate methods. Follow manufacturer protocols exactly 
(http://www.ebc.uu.se/digitalAssets/176/176882_3qubitquickrefcard.pdf), 
L1-seq library preparation 
1. Before beginning the relevant library prep PCRs, it is necessary to determine which samples 
will be pooled together in the library preparation. As many as ten samples can be pooled together 
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without using barcoding (notes). Equal amounts of each sample must be put into the DNA pool 
to be used in the library. A total of 24 ɥL of pooled DNA at a concentration of 100 ng/ɥL is 
needed. If there is not enough DNA available from one or more samples, a modified protocol can 
be used (notes). 
2. Round 1 PCR: Linear amplification of L1 flanks followed by a hemi-specific PCR 
incorporating the Illumina sequencing primer (Fig 5.1). To prevent running out of master mix, 
make enough for 9 reactions even though only 8 reactions will be assembled. Master mix (per 1 
reaction): 10 ɥL of Promega Go-Taq flexi buffer (5X), 6 ɥL of MgCl2 25 mM, 2 ɥL of L1SP1A2 
primer 20 ɥM, (the second primer for the reaction, the degenerate primers previously mentioned, 
will be added following the completion of 5 cycles of the PCR which consists of the linear 
amplification step), 0.5 ɥL of DMSO 100%, 0.5 ɥL of FlexiTaq, 1 ɥL of dNTPs 10 mM, 2 ɥL of 
pooled DNA (at 100 ng/ɥL), 24 ɥL of DEPC water. The reaction should total 46 ɥL before the 
addition of 4 ɥL of the degenerate primers to be added after linear amplification is finished. 
When the linear amplification is finished, add 1 of each of the degenerate primers at 5 ɥM (e.g. 
DEGSeq1N5TCTGT) to each of the 8 reactions. Use the following cycling program: 
L1-Seq PCR 1: 
1) 95 C for 2 minutes 30 seconds 
2) 95 C for 30 seconds 
3) 58 C for 1 minute 
4) 72 C for 2 minutes 
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5) Go to step 2 (5x) 
6) 60 C (pause and add 4 ɥL of degenerate primer into each of the 8 reactions, one primer per 
reaction for each of the 8 different degenerate primers) 
7) 95 C for 30 seconds 
8) 55 C for 30 seconds 
9) 72 C for 1 minute and 30 seconds 
10) Go to step 7 (14x) 
11) 72 C for 10 minutes 











Figure 5.1: The first PCR consists of five cycles which enrich for sequences containing human-
specific L1 sequences via primer extension with the L1Sp1A2 primer using diagnostic nucleoties 
for the human specific subfamily of L1. After enrichment for human-specific L1 flanks in the 
first 5 cycles, each reaction has one degenerate primer added. There are 8 degenerate primers, 
each with a specified 5-mer at the 3′ end preceded by five degenerate bases (NNNNN) and a 
sequencing primer used for the Illumina platform. Eight different reactions are performed, each 
with a unique 5mer. The second PCR enriches for human-specific L1 3′ flanks by utilizing 
another diagnostic nucleotide in the 3’ UTR of L1 and adds the necessary adapter sequences via 
primer overhangs. The products of this reaction are mixed in equimolar ratios before sequencing 
on the Illumina 2500 platform. Following sequencing and initial processing, the reads are aligned 




3. Purify all 8 reactions on 8 separate Qiagen PCR Clean-up columns following the Qiagen 
protocol, eluting in 50 ɥL of pre-warmed (55 C) EB (do a 10-minute final incubation before 
elution to optimize DNA eluted from column). 
4. L1-Seq PCR 2: Amplification of library and addition of the Illumina sequencing adapters (Fig. 
1). Master mix (for 1 reaction): 12.5 ɥL of master mix (Promega GoTaq Green 2X), 1.5 ɥL of 
primer Adap1L1HsG 20 mM, 1.5 ɥL of Adap2Seq1 20 ɥM, 2.5 ɥL of purified round 1 product 
(1 degenerate primer per reaction), 7 ɥL of DEPC ddH2O. Again, make enough for 9 reactions to 
prevent running out of master mix for the samples to be amplified. The reactions will each have a 
total of 25 ɥL. Use the following cycling program: 
L1-seq PCR 2 
1) 95 C for 2 minutes 
2) 95 C for 30 seconds 
3) 62 C for 30 seconds 
4) 72 C for 1 minute 
5) Go to 2 (19x) 
6) 72 C for 5 minutes 
7) 4 C Hold 
5. Resolve products on a 1% TAE gel. 
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6. Excise the constellation of bands between 200- 500 nucleotides with a sterile scalpel (using a 
different scalpel for each reaction) and purify the DNA using the Qiagen Gel Purification 
protocol. 
7. Elute the library in 50 ɥL of pre-warmed EB buffer (55C with a 10-minute incubation before 
elution). 
8. Run each DNA sample on the Agilent Bioanalyzer with the DNA 1000 kit to get an accurate 
measure of concentration and the average size of the DNA amplified. Using the concentration 
and average size of the molecules, calculate how to add the DNA from all 8 reactions in 
equimolar ratios to one tube. 
9. After mixing the DNAs together, purify the entire mixture with the Qiagen MinElute PCR 
purification kit eluting in 50 ɥL of pre-warmed EB (55C and 10-minute incubation at room 
temperature before elution). 
10. End-polishing must be performed on the library because Taq leaves adenine overhangs which 
could cause problems when the library is annealed to the Illumina flow cell. To accomplish the 
end-polishing: mix 6 ɥL of 10x Pfu buffer, 2.5 ɥL of Pfu polymerase, 2.5 ɥL of dNTPs 10 mM, 
and 49 ɥL of library. Incubate for one hour at 72C. 
11. Purify reaction on a Qiagen MinElute column and elute in 10 ɥL of pre-warmed (55C) EB 
following a 10-minute room-temperature incubation before elution. 
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12. Measure final DNA concentration with QubitTM fluorometer to get an accurate 
concentration for sending samples for next-generation sequencing on the Illumina HiSeq 2500. 
Opt for single end sequencing and at least 100 bp reads. 
3.5 Analyzing the Next-generation sequencing data 
1. Obtain the sequencing reads from the core or center where the samples were sequenced and 
transfer them into the L1-seq directory on the server in which all the correctly formatted L1-seq 
scripts reside. These scripts can be acquired from https://github.com/adamewing/l1seq. 
2. Obtain the contents of a database with all reference L1 insertions and polymorphic L1 
insertions which have been previously published to use for filtering sequencing data. A database 
of L1 insertions may be obtained at: http://nar.oxfordjournals.org/content/43/D1/D43(339). 
3. Once the documents are downloaded through the terminal, they must be unzipped. To unzip 
the fastq.gz files type “gunzip –d FILE_NAME.fastq.gz &” (the & symbol allows the unzipping 
to run in the background so that you can set all the files and can unzip simultaneously by typing 
this command for each file in turn.) 
4. After the files are unzipped, use the script to run bowtie and create indices for your data. You 
can execute this process with the command “./run_bowtie.py/whatever_fastq 
/directions/to/bowtie directions/to/hg19.fa &”. For any process which takes more than 10 
minutes, it is helpful to use the screen function by typing “screen –rAad” which will allow for 
the monitoring of all the processes simultaneously running. It also enables the user to monitor the 
total memory being used for analysis and the length of time each process has been running. 
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5. Once the run_bowtie script finishes, run the l1seq.py script as follows: “./l1seq.py –bam 
whatever.ba, > whatever.l1seq.txt &” 
6. Once all of the L1-seq.txt files are made, all the files need to be compressed for sorting. To 
compress the files, type “bgzip whatever_l1seq.txt &” 
7. To sort the files, type “tabix –s 1 –b 3 –e 4 watever.l1seq.txt.gz &” 
8. All the files must be compared to one another (e.g. normal compared with tumor etc.) to do 
this analysis, type “./compare.py group1_L1seq.txt.gz group2_l1seq.txt.gz group3_l1seq.txt.gz > 
filename_for_comparisons.tsv &” 
9. Finally, after the comparison file has been made, primers must be designed for validation of 
the data. It is best to run the makeprimers.pl script on the entire comparison file before looking at 
the data because the script does not take long to run and having the primer sequences ready to 
order is very useful. To run this final script, type “./makeprimers.pl 
filename_for_comparisons.tsv > filename_for_comparisons_with_primers.tsv &”. Use sftp to 
transfer the files back to your local computer if desired. 
Validating the Predicted Insertions from L1-seq with Site Specific PCR 
1. The presence of nonreference insertions is validated with site specific PCR (Figure 5.1). If the 
samples are not barcoded, all samples in a pool must be evaluated for the presence or absence of 
a predicted insertion. The DNA from each input sample from a pool needs to be at 12.5 ng/ ɥL 
and 2 ɥL of DNA used per reaction. The primers will be named by the makeprimers.pl script as 
“filled site” or FS and “empty site” ES refer to figure 5.1 for orientation of primers with regard 
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to the potential insertion. For each validation to be complete, the FS and L1SP1A2 primer 
reaction needs to be performed on all samples in the pool from which the prediction came. If 
comparing two states of the same tissue such as tumor and normal and the insertion is predicted 
only in one, the reaction must also be performed on both DNA samples. A control reaction can 
also be performed with the “empty site” or ES primer and the FS primer. Both the FS and ES 
primers are genomic and will produce a product of predetermined size in any DNA sample 
regardless of presence or absence of an insertion. 
2. For the FS/L1SP1A2 (filled site PCR) use the following master mix (1x): 12.5 ɥL of Promega 
GoTaq green (2X) master mix, 0.8 ɥL of FS primer 20 ɥM, 1.6 ɥL of L1SP1A2 20 ɥM, 2 ɥL of 
genomic DNA (12.5 ng/ɥL), 8.2 ɥL of DNase free H2O. For the FS/ES primers (empty site PCR) 
use the following master mix (1X): 12.5 ɥL of Promega GoTaq green (2X) master mix, 1 ɥL of 
FS primer 20 ɥM, 1 ɥL of ES primer 20 ɥM, 2 ɥL of genomic DNA (12.5 ng/ɥL), 9.5 ɥL of 
DNase free H2O. Use the following parameters for the PCR: 
3’ L1 Validation PCR 
1) 95 C for 2 minutes 
2) 95 C for 30 seconds 
3) 57 C for 30 seconds 
4) 72 C for 1 minute and 30 seconds 
5) Go to step 2 (29x) 
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6) 72 C for 5 minutes 
7) 4 C Hold 
3. Run the PCR products on a 1.5% TAE gel to resolve the products. Take images of the gel 
while it is exposed to UV to visualize the products. Excise fragments which are unique to only 
one of the samples upon which the PCR was run (Fig 5.2B). Isolate the DNA from the band and 
send for sequencing. If no clear filled site band is uniquely present in one of the samples tested, a 
nested PCR may be necessary (Fig 5.2A). Alternatively, the PCR conditions can be further 












Figure 5.2: A) Diagram of the PCR validation scheme for putative insertions, the 3’ end of the 
LINE-1 insertion is pictured adjacent to a poly A tail. The nested empty site and filled site 
primers are flanking the empty and filled site primers. In a nested PCR, the nested primers are 
used in the first of two reactions. One and a half uL of product from the first reaction (with ES 
and FS primers) are used as template in a second PCR with the nested primers to amplify 
difficult or rare products. B) Two examples of validations for insertions present in only tumor 
and absent from normal DNA. On the left, a PCR result depicting both the empty site (ES) and 
filled site (FS) products for both the normal and tumor DNA samples from patients. Only in the 
tumor of patient 11 is a filled site band present confirming the insertion is present. In the image 
on the right side on Figure 5,2 B, a PCR depicting another validation of a somatic insertion 
present in BE and absent from normal esophageal and white blood cell DNA. There is only a 
band present in the BE sample for the FS PCR; however, the ES PCR has bands for all three 
DNA samples as a positive control. C) An insertion sequence with the unique genomic DNA 




4. Finally, send the DNA for Sanger sequencing to ensure it is the correct product. Sequence the 
product with both the FS primer as well as the L1SP1A2 primer. When the sequence from the FS 
is aligned to the genome with BLAT or another alignment algorithm, part of the sequence should 
align to the genome and a poly T tract should also be visible adjacent to the aligning sequence. 
For the sequence from the reaction performed with the L1 specific primer, the 3’ end of the L1 
should be visible in addition to the poly-A tail (Fig 2C). 
5. To find the 5’ end of the insertion, several different methods can be utilized. Because many 
new L1 insertions are truncated on the 5’ end of the element, it is frequently possible to detect 
the 5’ end of the element by using the reverse complement of the L1SP1A2 primer (L1 GTG 
primer) with the ES primer. To do this, make the master mix as follows: mix (1x): 12.5 ɥL of 
Promega GoTaq green (2X) master mix, 0.8 ɥL of ES primer 20 ɥM, 1.6 ɥL of L1 GTG primer 
20 ɥM, 2 ɥL of genomic DNA (12.5 ng/ɥL), 8.2 ɥL of DNase free H2O. For insertions with a 
longer 5’ end present, this PCR will likely fail; however, it is possible to tile across the L1 
element with various primers at different locations (e.g. L1nt112out) in the element accompanied 
by the empty site primer to find the 5’ end. For this PCR, use the following master mix (1X): 
12.5 ɥL of Promega GoTaq green (2X) master mix, 0.8 ɥL of ES primer 20 ɥM, 1.6 ɥL of L1 
internal primer 20 ɥM, 2 ɥL of genomic DNA (12.5 ng/ɥL), 8.2 ɥL of DNase free H2O. 
5’ L1 GTG PCR parameters: 
1) 95 C for 2 minutes 
2) 95 C for 30 seconds 
3) 57.5 C for 1 minute and 30 seconds 
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4) 72 C for 3 minutes 
5) Go to Step 2 (29x) 
6) 72 C for 5 minutes 
7) 4 C Hold 
5’ L1 internal primer (e.g. L1nt112out) PCR parameters: 
1) 95 C for 2 minutes 
2) 95 C for 30 seconds 
3) 57 C for 30 seconds 
4) 72 C for 45 seconds 
5) Go to step 2 (29x) 
6) 72 C for 5 minutes 
7) 4 C Hold 
Notes 
1. If very little DNA is available for both library prep and validation PCRs, L1-seq can still be 
successfully performed. L1-seq has successfully been executed with as little as 25 ng of input per 
sample for the library prep. For the steps following next-generation sequencing, whole genome 
amplification can be used (e.g. the Qiagen Repli-G kit) to provide more DNA to use for the 
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validation PCRs. If adjusting the amount of DNA used, be sure to account for volume changes 
and the concentrations of the other reagents to ensure all final concentrations are the same as 
described in the original technique. 
2. Occasionally, one of the degenerate primer reactions will not be as robust as the other 
reactions and when the libraries are run on a gel, the amount of DNA present is variable between 
reactions. This may not be an issue if there is enough DNA present after the gel purification for 
the samples to easily be mixed in equal amounts. However, if the concentration of the DNA 
isolated from the gel purification step is too little to continue without grossly diminishing the 
amount of total DNA in the combined library, simply repeat the second reaction of L1-seq and 
combine the isolated DNA from both gel purifications and concentrate the DNA. If the DNAs 
from the respective degenerate primer reactions are run on the Bioanalyzer and produce very 
different size distributions of products, it may be necessary to repeat the second L1 PCR again 
on that DNA sample as well. Ideally, the average product size for each degenerate primer 
reaction should be within one standard deviation of 350 nucleotides. If the size varies more than 
one standard deviation from 350, the reaction should be repeated and rerun on a gel. If the size is 
wrong, it is likely that the excision was initially imprecise. 
3. When first performing L1-seq it is prudent to execute a TA cloning step after completing the 
libraries and mixing them in equimolar ratios, but before completing the end-polishing step. To 
do this, simply take one ɥL from the mixed libraries and use it in a Topo TA cloning reaction. 
Follow kit instructions and after growing colonies overnight, select 12 or more from each plate 
for colony PCR. Following colony PCR, run the product on a gel to be sure the cloning worked 
effectively, select some or all of the successful clones for Sanger sequencing. When analyzing 
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the Sanger sequencing, look for different L1Ta elements from many different areas of the 
genome. Essentially, this is a step to check that the library does not consist of amplicons of only 
a handful of LINE-1 elements in the genome and that elements in the genome are equally 
represented in the library. This step does not need to be performed for every library prep; 
however, if a problem occurs with next-generation sequencing, this step could consequently be 
taken to determine whether or not overrepresentation of a few elements precluded successful 
sequencing. 
4. If validation PCRs are unsuccessful after many attempts, be sure to check the specificity of the 
primers being used in the amplification. Oftentimes, it is helpful to perform a nested PCR 
following the first conventional PCR to amplify difficult or low-copy insertions which may have 
been easily detectable with next-generation sequencing and not with Sanger sequencing. You can 
nest both the filled site primers as well as the L1Ta specific primers to increase the specificity of 
the reaction greatly. Nested PCR along with an increase in cycle numbers and/or altering the 
melting temperature of the PCR often alleviates validation PCR issues. 
5. If the DNA being measured at any point in the library prep is at a low concentration and 
undetectable with the standard QubitTM broad range kit or the Agilent 100 DNA chip, there are 
low concentration versions of these reagents available. 
6. Barcoding may also be utilized with this technique; however, results may vary. In 2012, 
Evrony et al. performed L1-seq using barcoding and were able to validate some new LINE-1 
insertions following sequencing analysis. However, other groups have had more difficulty 
getting the technique to work well and seem to have more success with pooling samples without 
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barcodes. Pooling samples without barcodes does create more work for the validation steps of 
the technique; however, it seems to have more reproducible results. 
7. With regard to choosing predicted insertions for validation, one of two main methods may be 
employed. A random number generator can be used to select putative somatic insertions for 
validation which will potentially give a good estimate of the number of true somatic insertions in 
the dataset. Alternatively, putative somatic insertions with unique read counts above 5, map 
scores of 1, and alignment windows of at least 100 base pairs can be selected for validation. 
Depending on the validation rate with the primary insertions selected, the level of stringency can 
be altered until the ideal validation rate is achieved. A validation rate above 60% is generally 
acceptable for this technique; however, PCR optimization, good primer design, and good DNA 
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